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Pancreatic cancer is one of the most lethal type of cancer due to its high 
metastasis rate and resistance to chemotherapy. Pancreatic fibrosis is a constant 
pathological feature of chronic pancreatitis and  the hyperactive stroma 
associated with pancreatic cancer. Strong evidence supports an important role of 
cyclooxygenase-2 (COX-2) and COX-2 generated prostaglandin E2 (PGE2) 
during pancreatic fibrosis. Pancreatic stellate cells (PSC) are the predominant 
source of extracellular matrix production (ECM), thus being the key players in 
both diseases. Given this background, the primary objective is to delineate the 
role of PGE2 on human pancreatic stellate cells (PSC) hyper activation 
associated with pancreatic cancer.  
This study showed that human PSC cells express COX-2 and synthesize 
high levels of PGE2. PGE2 stimulated PSC migration and invasion; expression of 
extra cellular matrix (ECM) genes and tissue degrading matrix metallo 
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proteinases (MMP) genes. I further identified the PGE2 EP receptor responsible 
for mediating these effects on PSC.  Using genetic and pharmacological 
approaches I identified the receptor required for PGE2 mediates PSC hyper 
activation. Treating PSC with Specific antagonists against EP1, EP2 and EP4, 
demonstrated that blocking EP4 receptor only, resulted in a complete reduction 
of PGE2 mediated PSC activation. Furthermore, siRNA mediated silencing of 
EP4, but not other EP receptors, blocked the effects of PGE2 on PSC fibrogenic 
activity. Further examination of the downstream pathway modulators revealed 
that PGE2 stimulation of PSC involved CREB and not AKT pathway. 
The regulation of PSC by PGE2 was further investigated at the molecular 
level, with a focus on COL1A1. Collagen I deposition by PSC is one of the most 
important events in pancreatic cancer. I found that PGE2 regulates PSC through 
activation of COL1A1 expression and transcriptional activity. Downstream of 
PGE2, silencing of EP4 receptor caused a complete reduction of COL1A1 
expression and activity supporting the role of EP4 mediated stimulation of PSC. 
Taken together, this data indicate that PGE2 regulates PSC via EP4 and suggest 
that EP4 can be a better therapeutic target for pancreatic cancer to reduce the 
extensive stromal reaction, possibly in combination with chemotherapeutic drugs 
can further kill pancreatic cancer cells. 
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CHAPTER ONE: INTRODUCTION 
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INTRODUCTION TO THE PANCREAS 
A brief overview of the development, anatomy, function and histology of 
the pancreas is discussed below. For a more thorough description please refer to 
references 1-3.(1) 
 
Anatomy and physiology  
The human digestive system is composed of the salivary glands, the liver 
and the pancreas. The pancreas is an elongated organ is situated in the center of 
the abdomen, behind the stomach.  The pancreas is composed of a head, neck, 
body and tail.  The head of the pancreas is the widest part and it lies in the 
duodenum while the tapered left side of the pancreas referred to as the body 
ends near the spleen. It is surrounded by numerous structures and important 
blood vessels.  
In humans, the pancreas weighs on average 80 g and is 15 to 20 cm long (1). 
During embryogenesis, the dorsal and ventral buds join to form the pancreas. 
The duct that forms from the duodenum becomes the duct of Santorini, whereas 
the duct forms from the hepatic diverticulum and gives rise to the duct of 
Wirsung. The duct of Wirsung collects pancreatic juice and empties it in the 
duodenum. With gut rotation, the ventral bud becomes the pancreatic head and 
fuses with the dorsal bud, which becomes the body and the tail of the pancreas. 
The ducts of both buds fuse together and drain in the pancreatic head where the 
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duct of Wirsung becomes the main pancreatic duct. Enzymes needed for the 
digestion of carbohydrates, fat and proteins continuously flow through the ducts.  
The ducts fail to fuse in a small percentage of patients which results in mal 
function of the pancreas. 
 
Function and histology 
The pancreas is composed of two glands: The exocrine gland and the 
endocrine gland.  In adults, most of the activity of the pancreas is dedicated to 
the exocrine gland. The exocrine pancreas and salivary glands share structural 
similarities and is controlled by both hormonal and neural s signals. The exocrine 
component of the pancreas is composed of acinar cells, which makes up most of 
the exocrine pancreas. When the acinar cell is stimulated, it releases the 
enzymatic component of the pancreatic juice from the zymogen granules into the 
lumen of the acinus where it mixes with the secretions of the centroacinar cells. 
As the name indicates the centroacinar cell is the cell that is in the center of the 
acinus cell and is part of the ductal system. Under the microscope, the acinar 
cells look like blind ended tubules surrounded by polygonal acinar cells, which 
resembles a cluster of grapes, hence the name acinar cells which means grape 
in latin. The tiny ducts that drain the acini are called intercalated ducts. The 
intercalated ducts empty into larger intralobular ducts which in turn drain into an 
extralobular duct that empties into larger ducts and then into a main large duct 
that drains the pancreas and enters the duodenum. During this trajectory, the 
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pancreatic juice accumulates water, chloride and bicarbonates that are secreted 
by the duct cells to help neutralize the pH of the duodenal content (2). Each day 
the pancreas secretes 1L, more than 10 times its weight of pancreatic fluids. (3)  
These secretions contain amylases, proteases and lipases which aid in the 
digestion process of carbohydrates, proteins and fats. 
The endocrine cells of the pancreas form islets in the parenchyma called 
the Islets of Langerhans.  There are five types of cells in the Islets of 
Langerhans; about 75% of the cells in each islet are insulin producing beta cells. 
The remaining 25% of cells consists of alpha, delta and F cells which secrete 
glucagon, somatostatin and pancreatic polypeptide and are located at the 
periphery of each islet.  The hormones secreted by these cells are important in 
glucose homeostasis and GI functions such as bile secretion and nutrient storage 
(4). 
 
PANCREATIC DUCTAL ADENOCARCINOMA 
Epidemiology 
Pancreatic ductal adenocarcinoma (PDAC) is the most occurring type of 
pancreatic cancer and it affects the exocrine cells of the pancreas. Less than 1% 
of pancreatic tumors occur in the endocrine system (5). PDAC is now the fourth 
leading cause of cancer related death in the United States although it is ranked 
as 10th in the list of most occurring cancers (6). For the year 2010, it is estimated 
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that more than 43,000 individuals would have been diagnosed with pancreatic 
cancer and 36,800 have died from the disease (6). 
Pancreatic cancer is a disease of old individuals. Based on the SEER 
cancer statistics, only 13% of individuals are diagnosed before the age of 60 and 
more than 50% of the patients are 75 years old and older at the time of 
diagnosis(3).  Men are 30% more likely to develop pancreatic cancer than 
women. Blacks and Jewish people have a higher incidence of pancreatic cancer 
compared to Caucasians (7). At the molecular levels, blacks have more frequent 
k-ras mutations than Caucasians and Chinese people have a different 
expression of Ki-ras and p53 than Caucasians (8). 
There are many genetic and environmental risk factors for pancreatic 
cancer. Smoking is the strongest environmental factor for pancreatic cancer. 
Carcinogens from cigarette smoking enter the bloodstream and reach the 
pancreas after leaving the lungs. There is a strong correlation between smoking 
and pancreatic cancer(9). Studies show that the risk of pancreatic cancer 
increases by two folds in individuals that smoke compared to non smokers (10, 
11). An Important risk factor for pancreatic cancer is the diet. Dietary factors can 
either increase or decrease the risk of pancreatic cancer. Studies have linked 
increased caloric intake and obesity to increased risk of pancreatic cancer. On 
the other hand, increased intake of fruits and vegetables reduce the risk (12, 13). 
The lack of physical activity has also been reported as a risk factor for pancreatic 
cancer (14). Alcohol is a major risk for chronic pancreatitis however studies have 
failed to link alcohol consumption to pancreatic cancer. One of the problems 
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trying to link pancreatic cancer to dietary intake and environmental factors is due 
to the rapid progression of the disease and the lack of methods for early 
detection. Most studies are case control studies and at the time of diagnosis, the 
patients are in an advanced stage of the tumor that unable them to respond to 
changes in the diet usually incorporated early on as a chemo preventive 
measure.  However, studies have shown a strong correlation between 
preexisting conditions and the risk for pancreatic cancer (15, 16). Alcoholic and 
non alcoholic pancreatitis results in an increase of up to 20 folds for pancreatic 
cancer. For tropical and hereditary that develops early on the risk for pancreatic 
cancer is much higher, up to 40% for patients with hereditary pancreatitis. It is 
not clear whether diabetes is a risk for pancreatic cancer since it can be one of 
the earlier symptoms of the disease, however many studies have shown that 
diabetics have a 2 fold increased chance of developing pancreatic cancer (17).  
Mutations in genes such as BRCA1 (18), BRCA2 (19, 20), 
p16/CDKN2A(21) and others (20, 22) that are commonly altered in many 
cancers, are associated with an increased risk for developing pancreatic cancer . 
The most important genetic alteration is that of BRCA2 which is found in up to 
10% of patients with sporadic pancreatic cancer and up to 20% of patients with a 
family history (23). Most diseases that increase the risk of pancreatic cancer are 
autosomally dominant inherited, however, autosomal recessive diseases such as 
ataxia-telangiectasia (24), fanconi anemia (25)  and cystic fibrosis (26, 27) have 
been reported to be linked to the disease.  
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Detection and diagnosis of pancreatic cancer 
Pancreatic cancer is called “the silent disease” and one of the major 
reasons why pancreatic cancer survival is low, is because the symptoms don’t 
start to appear until more advances and incurable stages. Most patients show 
sudden weight loss. Jaundice is also seen in a number of patients, when the 
tumor blocks the bile duct and prevents bile passing to the digestive system, 
usually these patients have a better prognosis because the tumor is located at 
the head of the pancreas and is resectable. However, tumors that develop at the 
tail of the pancreas are usually harder to detect and are asymptomatic therefore 
patients have a lower survival rate (28). The most common symptom reported in 
around 80% of patients with locally advanced pancreatic cancer is epigastric pain 
when eating or lying down. As with other types of cancers, nausea, loss of 
appetite and fatigue are reported. Even though it is uncertain whether diabetes is 
directly correlated with pancreatic cancer, patients over 50 years old that develop 
diabetes  are usually tested for pancreatic cancer (29).  
Currently, two imaging regimes are used to detect pancreatic cancer MRI 
(magnetic resonance imaging) and EUS (endoscopic ultrasonography). Standard 
radiological testings and CT scans are used for the detection of pancreatic 
cancer; however, they are not sensitive enough to detect small early staged 
tumors (30). Other methods like PET (positron emission tomography) are used to 
detect metastases. Commercially available tumor marker for pancreatic cancer 
CA19-9, is used to monitor the therapeutic response of patients. However, 
limitations such as the percentage of patients with pancreatic cancer do not 
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secrete CA19-9 (10-15%) and the normal range of CA19-9 in patients with small 
local tumors prevents CA19-9 from being used as a screening marker(31). Even 
though CA19-9 is not used for diagnosis and detection of pancreatic cancer, it 
strongly correlates with the progression of the disease and the response to 
treatment. In many cases, even when the physician suspects pancreatic cancer 
imaging tests fail to detect the tumor therefore biomarkers are needed to facilitate 
diagnosis. For example, mutant K-ras is found in the pancreatic juice and in the 
stool of patients with pancreatic cancer however, K-ras cannot be used as a 
biomarker because of its presence among smokers and patients with chronic 
pancreatitis. K-ras is also associated with late stages of the disease therefore it is 
not an ideal biomarker (32). 
 
Management and staging of pancreatic cancer 
Pancreatic cancer staging is the most important factor in determining 
treatment methods and management. The American Joint Committee on Cancer 
(AJCC) use the TNM system to stage pancreatic cancer. T is the size of the 
primary tumor and whether it has spread within the pancreas or locally- the tumor 
is usually resectable, only 10-15% of patients belong to this category and are 
candidates for surgery. The tumor is usually located at the head of the pancreas 
and is detected early because of extreme pain. The Whipple procedure is 
performed to remove the tumor. The procedure is highly invasive and requires 
the removal of the duodenum, distal part of the stomach, gallbladder and the 
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common bile duct, therefore this procedure is associated with mortality ranging 
from 4-16%(33).The overall survival for patients with resectable pancreatic 
cancer is 20% over 5 year. All patients who undergo surgical removal of the 
tumor receive chemotherapy and radiation therapy. Recent studies show at least 
10% long term survival benefit when chemotherapy and radiation follow surgery. 
N describes the stage where the tumor has spread to regional lymph nodes- the 
tumor is locally advanced. M is the stage where the tumor has metastasized to 
other organs of the body. The numbers 0-4 indicate the severity of each stage-
the tumor is metastatic(34).  Tumors in the tail of the pancreas usually belong to 
the N or M stage because of the late detection. This tumor is usually not subject 
to surgery and chemotherapy slightly improves survival (35). Patients with locally 
advanced tumors and patients who are not candidates for surgery undergo 
palliative care to alleviate the pain. Jaundice is the most common symptom of 
pancreatic cancer and is due to bile obstruction. To alleviate symptoms and clear 
biliary obstruction associated with jaundice, endoscopic biliary stent insertion is 
used. This method is the primary method for non surgical palliation of jaundice in 
patients with pancreatic cancer. Incapacitating pain is another symptom of 
pancreatic cancer.  There are many causes of tumor associated pain that could 
be caused by tumor infiltration, obstruction of the GI tract, tumor pressure and 
more. Pain is usually treated by the administration of oral analgesics and at later 
stages by morphine (36). In several cases, palliative surgery is used to alleviate 
biliary obstruction, duodenal obstruction, and pain and to improve quality of life of 
patients.  
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Chemotherapy 
Up to 85% of patients are diagnosed with locally advanced pancreatic 
cancer and metastatic cancer, therefore cannot be treated with surgery (37). 
Adjuvant therapy with 5-fluouracil (5FU) combined with radiation had shown a 
survival benefit in a study done in the 1980s (38). Recent studies have shown 
greater long term survival in patients treated with 5FU after surgery compared to 
patients who did not receive chemotherapy, however studies show that 5FU 
combined with radiation showed no benefit (39).   Nowadays, Gemcitabine is the 
standard of care for patients with metastatic pancreatic cancer. Patients treated 
with Gemcitabine have shown higher survival than patients treated with placebo 
or 5FU (35). Therefore, Gemcitabine is considered first line therapy for advanced 
pancreatic cancer (40). Several new agents have been tested alone or in 
combination with Gemcitabine, however, the benefits were dismal. Gemcitabine 
(29,29-difluoro 29-deoxycytidine, dFdC) is a cytidine analog. Like its analog Ara-
C, Gemcitabine is a prodrug and is activated by cellular uptake and intracellular 
phosphorylation by deoxycytidine kinase (dCK) into gemcitabine monophosphate 
(dFdCMP) which is then converted into gemcitabine di (dFdCDP) and 
triphosphate (dFdCTP), the active metabolites(41). Gemcitabine has many 
antitumor effects (42); it inhibits DNA synthesis(43), DNA polymerase, induces 
apoptosis and is incorporated in the DNA. Its location in the DNA chain prevents 
its detection by DNA repair enzymes (44). Pancreatic cancer cells are highly 
resistant to Gemcitabine. Resistance is either acquired after treatment or the 
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patient is resistant from the beginning. The response to Gemcitabine varies 
between patients and this is mostly due to changes in the intracellular levels of 
the metabolites and in the activities of drug transporters and enzymes involved in 
the metabolism of the drug (45). An important determinant of a patients response 
to Gemcitabine treatment is the intracellular retention of gemcitabine nucleotides 
particularly gemcitabine tri phosphate. 
 
Resistance to chemotherapy 
As mentioned previously, most new trials have not shown significant 
survival advantages and Gemcitabine is still the first line therapy for unresectable 
pancreatic cancer. Preclinical investigations have identified many molecular 
mechanisms that contribute to the resistance of pancreatic cancer to therapy.  A 
recent study shed the light on the tumor vasculature of pancreatic cancer (46).  
Pancreatic cancer is hypovascular and poorly perfused. The poor network of 
blood vessels impedes proper delivery of chemotherapeutic agents and increase 
drug resistance (46). Another aspect of pancreatic cancer chemoresistance is the 
alteration of genes involved in gemcitabine transport and metabolism. The 
human equilibrative nucleoside transporter -1 (hENT-1) is the major gemcitabine 
transporter in cells. In the absence or malfunction of hENT-1 gemcitabine cannot 
exert its antiproliferative effects (47, 48). Low expression of hENT-1 In patients 
correlates with low survival and bad prognosis (49). One of the most studied 
mechanisms of pancreatic cancer resistance are related to ABC (ATP binding 
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cassette) highly expressed in cancer cells and cancer stem cells (50). As 
discussed previously, deficiency in dCK which phosphorylates gemcitabine into 
its active form increases resistance. It has been reported that resistant pancreatic 
cancer cell lines have reduced activity of dCK (51). Anti-apoptotic molecules are 
overexpressed in pancreatic cancer which causes the cancer cell to evade 
apoptosis thus reduces their chemosensitivity. For example, bcl-XL expression 
levels are high in 82% of patients (52). Upregulation of bcl-2 has also been 
correlated with increased resistance to gemcitabine (53) On the other hand, pro-
apoptotic molecules are downregulated, for example BNIP3 expression is low in 
almost 90% of patients (54) . The transcription factor nuclear-factor kappa B (NF-
kappaB) is constitutively expressed in pancreatic cancer and promotes tumor 
grown, invasion, angiogenesis and chemoresistance (55, 56). The inhibition of 
NF-KappaB increases chemo sensitivity and improves the outcome of pancreatic 
cancer (55, 57). 
 Accumulating evidence shows that the dense tumor associated 
desmoplasia plays a central role in chemo resistance. A recent study that uses 
gemcitabine in combination with IPI-926 a hedgehog inhibitor that depletes the 
stroma show increased survival and drug delivery compared to gemcitabine 
treatment alone (46) therefore, desmoplasia hinders proper drug delivery and 
might cause pancreatic cancer resistance to chemotherapy.   
 
Pancreatic desmoplasia 
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The hallmark of both chronic pancreatitis and pancreatic cancer is the 
extensive fibrosis that develops in the pancreas. Pathological fibrosis is the 
formation or development of excess fibrous connective tissue as a reparative or 
reactive process. The fibrotic reaction that surrounds the pancreatic tumor tissue 
is called desmoplastic reaction (Figure 1). This dense desmoplasia characterizes 
the majority of pancreatic cancers (58), with the cancer cells constituting only a 
minor population of the whole tumor mass. The stroma of pancreatic cancer is 
composed of interstitial connective tissue mostly made of collagen I and 
fibronectin, growth factors, inflammatory cells, new blood vessels, endothelial 
cells, nerve cells, immune cells such as macrophages, dendritic cells and stellate 
cells. The pancreatic stellate cell (PSC), which will be discussed in the next 
section in more detail, is the major cell responsible for the production of the 
desmoplastic reaction (59).  Pancreatic tumor-stroma interactions are 
bidirectional. Formation of new blood vessels in the stroma has been shown to 
facilitate pancreatic tumor cell invasion (60). The stroma has also been 
correlated with the degree of aggressiveness of pancreatic tumors; tumors that 
have a less prominent stromal reaction are less likely to be aggressive (61).  On 
the other hand, the tumor also influences the stroma. One example is the 
secretion of TGF-b by tumor cells which increases the production of Collagen I 
and Connective Tissue Growth Factor (CTGF) by the stroma (62). Understanding 
the molecular and cellular mechanisms of the stroma and how the tumor-stroma 
interactions are influenced will be critical for identifying potential therapeutic 
targets for pancreatic cancer.  
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Figure 1. Desmoplastic reaction surrounding the tumor mass in 
PDAC 
 
 
 
 
 
 
 
 
  
 
15 
 
Pancreatic Stellate Cells (PSC) 
Initiation 
Pancreatic stellate cells are the principle source of fibrosis in both chronic 
pancreatitis and pancreatic cancer (59, 63). Stellate cells are resident cells of the 
pancreas, located at the basolateral aspect of acinar cells and constitute 
approximately 4% of pancreatic cells (64). In the normal pancreas, stellate cells 
are quiescent, identifiable by the presence of vitamin-A containing lipid droplets 
in the cytoplasm (65) and positive immunostaining for cytoskeletal proteins such 
as desmin and glial acidic fibrillary protein, which are the adopted way to identify 
quiescent PSC. One of the normal physiological roles of PSC is in extracellular 
matrix turnover via their ability to synthesize matrix proteins as well as matrix-
degrading enzymes, MMPs. It has been suggested that PSC are involved in 
maintaining pancreatic acinar cells because of their location around the acini. 
Because of their periductal and perivascular location, PSC might be involved in 
normal duct and vascular regulation in the pancreas (66).   
Activation 
During inflammatory injury, PSC undergo various changes in their morphology 
and behavior, they become activated and assume a myofibroblast-like phenotype 
characterized by the loss of vitamin A droplets, the production of -SMA and 
extracellular matrix proteins such as collagen Ia1 and III, fibronectin and laminin  
(64). In vitro studies have identified several factors involved in the activation of 
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PSC such as alcohol (ethanol), cytokines (IL-1, IL-6), growth factors (platelet 
derived growth factor; PDGF, TGF-b1, activin A), oxidative stress and pressure, 
and changes in extra cellular matrix (67, 68). Other cells in the pancreatic 
microenvironment such as macrophages, platelets and endothelial cells as well 
as acinar cells and cancer cells are the source of PSC activating factors (67, 68).  
Activated PSC proliferate, migrate, increase the production of extra cellular 
matrix molecules as well as ECM related molecules and secrete cytokines and 
chemokines (66, 69). Chemokines produced by PSC recruit inflammatory cells to 
the pancreas. Cytokines and growth factors produced by PSC themselves and 
other neighboring cells (acini, tumor, immune cells, platelets or any other cell in 
the microenvironment) activate PSC and the reaction is bidirectional. Activation 
occurs in both paracrine and autocrine manner (70). It has been suggested that 
autocrine activation of PSC by cytokines like TGF-b, sustain the fibrotic response 
and allows it to perpetuate after stimulation by the initial signal, which promotes 
desmoplasia (33, 63). PDGF and TGF-b are believed to be the most potent 
activators of PSC. PDGF induces the proliferation and migration of PSC (71, 72), 
whereas TGF-b induces the expression of the activation marker alphaSMA and 
ECM proteins to sustain the activation of PSC (73, 74). As mentioned previously, 
PSC are involved in maintaining normal tissue architecture and ECM turnover, 
and were shown to secrete MMPs (matrix metalloproteinases) such as MMP2, 
MMP9 and MMP13, and TIMPs 1 and 2 (tissue inhibitors of matrix 
metalloproteinases) (69) which could impact the invasion and metastatic potential 
of pancreatic cancer. MMP2 is known to degrade collagen IV, an essential 
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component of the basement membrane, thereby facilitating the deposition of 
fibrillar collagen type I observed in pancreatic fibrosis. PSC promote the 
angiogenic potential of cancer cells, so far two mechanisms have been identified. 
The first mechanism involved the secretion of proteolytic matrix degrading MMP-
2 enzyme. Increased MMP2 expression by PSC has been shown to accelerate 
pancreatic tumor progression (75) .The second known mechanism by which PSC 
increase angiogenesis is by the production of proangiogenic factors such as 
VEGF. When active, PSC constitutively produce vascular endothelial growth 
factor (VEGF) and other angiogenic molecules such as VEGF receptors (flk-1, flt-
1) and others (76). Therefore, PSC play a profibrogenic and proangiogenic role, 
and tumor induced PSC activation lead to increased angiogenesis, which could 
promote pancreatic cancer progression by delivering oxygen and nutrients to the 
hypovascular tumor in order to increase growth, invasion and metastasis.  
Postactivation 
Following activation, PSC have one of two fates depending on the severity of the 
injury. If the injury is limited, activated PSC lose their active phenotype and 
become quiescent again. PSC might also undergo apoptosis.  In the latter two 
cases, fibrosis does not occur. If the inflammatory is severe and repeated, PSC 
activation is sustained and perpetuated and pancreatic fibrosis develops. 
Repeated and sustained injuries to the pancreas are important for the 
development of fibrosis. From this point on, pancreatic fibrosis is defined as the 
pathological changes of extra cellular matrix composition, both in quality 
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(collagen IV is replaced by collagen I and quantity (excessive collagen I 
deposition) , caused by the irreversible activation of PSC. 
Origin of PSC 
There are many speculations about the embryonic origin of PSC. PSC share 
similarities with their hepatic counterpart, hepatic stellate cells (HSC). Both cells 
express alphaSMA, GFAP, and transcriptome analysis studies revealed 99.9% 
homology at the mRNA level (77). This might suggest that PSC and HSC share a 
common origin but have organ specific variations that could be due to the 
different microenviromental factors the cell is exposed to. A different study 
demonstrated that PSC are derived from a pancreas-specific precursor (78).  
Activated PSC are thought to arise from quiescent PSC in the pancreas. 
However, studies done on mice with sex-mismatched bone marrow (BM) 
transplantation from a male mouse carrying enhanced GFP to female mouse 
suggest that a small subgroup of PSC, approximately 5%, is derived from the BM 
(79).  
 
Molecular regulation of PSC 
PPAR- is a member of the PPAR family of nuclear hormone receptors. 
Upon dimerization with RXR, PPAR- binds PPAR response elements in the 5’ 
flanking region of target genes, therefore controlling cell proliferation, 
macrophage function and immunity (80). Negative regulation of PPAR- is 
associated with PSC activation and overexpression of PPAR- results in the loss 
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of PSC activation (81). Therefore, PPAR- is involved in maintaining the 
quiescence of PSC.  
Rho and Rho kinase are also involved in the regulation of PSC.  
Incubation of quiescent PSC with Rho kinase inhibitors (HA-1077 and Y-27632) 
blocks the activation of  freshly isolated PSC in culture on plastic (74). Rho 
kinase inhibitors also inhibit stress fiber formation associated with activated PSC 
migration and contraction in response to endothelin-1(82). 
In activated PSC, a variety of stimuli activate the MAPK pathway including 
ERK and p38MAPK (83). Activation of MAPK increases the production of 
cytokines and chemokines by PSC. Studies show that inhibition of p38MAPK 
blocks the activation of PSC (84) therefore, p38 MAPK mediates PSC activation. 
ERK activation precedes alphaSMA expression and mediates PSC proliferation 
to different stimuli in response to PDGF (83). 
Phosphatidyl inositol 3 kinase (Pi3K)/ Akt pathway is also involved in the 
regulation of PSC. Activation of PSC correlates with activation of PI3k/Akt 
pathway (74). PDGF stimulates PSC migration via a PI3K/Akt dependent 
pathway mediates however it was not found to be involved in PSC proliferation 
(47, 85). 
TGF-b is a potent regulation of PSC; it can regulate PSC in SMAD 
dependent and SMAD independent mechanisms. The extra cellular matrix 
production by PSC is regulated by TGF-b in a Smad2 dependent manner (86) 
while TGF-b inhibits PSC proliferation by activating Smad3 dependent 
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downstream signaling. Treatment of PSC with MEK1 inhibitors results in a 
decrease in the mRNA levels of TGF-b1 thus demonstrating the involvement of 
ERK pathway in the regulation of TGF-b. 
Prostaglandin E2 (PGE2) 
Prostaglandins (PG) are 20-carbon fatty acid derivatives found in all tissues and 
organs. Diverse stimuli trigger PGs synthesis by the release of arachidonic acid 
(AA) from the plasma membrane by the action of phospholipase-A2 (PLA2). 
Upon its release from the plasma membrane, AA is converted to an unstable 
endoperoxide intermediate prostaglandin G2 (PGG2) by cyclooxygenases; this is 
rate limiting enzymatic reaction. PGG2 is then converted to an oxygenated 
intermediate prostaglandin H2 by the peroxidase activity of COX- enzymes. 
PGH2 is then metabolized by the action of cell specific synthases and is the 
precursor of several prostaglandins; PGE2, PGD2, PGF2a, PGI2 and TXA2 (87). 
Prostaglandins are released outside the cell immediately following their 
biosynthesis. PG actions are dependent upon their interactions with prostanoid 
specific G-coupled protein receptors, the focus will be on PGE2 and its four 
receptors EP1-4. The actions of prostaglansins could also be terminated when 
they are transported across the plasma membrane into the cytoplasm by 
prostaglandin transporters (88) where they are reduced or oxygenated by PG 
catabolizing enzymes (88, 89). 
Currently, there are three known COX isoforms COX-1, COX-2 and COX-
3 (a splice variant of COX-1). COX-1 is a ubiquitously and constitutively 
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expressed isoform that is postulated to have “housekeeping” functions with basal 
production of prostaglandins under homeostatic conditions. In contrast, COX-2 is 
encoded by an early-response gene and can be rapidly induced by growth 
factors, cytokines, inflammatory mediators and tumor promoters (20, 90). By 
immunohistochemistry (IHC), COX-2 was found to be highly expressed in chronic 
pancreatitis (91) and pancreatic adenocarcinoma (92-94) and is also found in 
precursor lesions associated with pancreatic cancer referred to as pancreatic 
intraepithelial neoplasia (PanIN) (95) . 
As mentioned previously, COX-2 is frequently overexpressed in many 
types of cancer including breast, colon, lung and pancreatic cancer (96-98). 
PGE2 has been identified as the major prostaglandin behind COX-2 
proneoplastic functions [100]. Many tumors that overexpress COX-2 have high 
intramural levels of PGE2. In pancreatic cancer, COX-2 overexpression was 
reported in 74-100% of patients, irrespective of the grade and histological type of 
the tumor (92, 95, 99). Furthermore, PGE2 promotes cell growth, angiogenesis, 
migration, invasion and survival in pancreatic cancer (100-102).  Many studies 
have implicated the role of PGE2 in carcinogenesis for a wide range of cancers 
including pancreatic cancer. However, the downstream targets by which PGE2 
mediate these processes are not fully understood.  
EP receptors subtypes 
PGE2 exerts its effects by binding to four membrane bound E-prostanoid 
(EP) receptors. In humans, there are four EP receptors EP1, EP2, EP3 and EP4. 
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EP receptors are G-protein coupled receptors (GPRCs) that are activated by the 
actions of PGE2. PGE2 binding to EP receptors produces a change in receptor 
conformation, exposing intracellular sites involved in the interaction with the G 
protein, consisting of α, β, and γ subunits. The interaction with the receptor 
causes the guanosine diphosphate (GDP) to be freed from the α subunit and 
replaced by guanosine triphosphate (GTP). The binding of GTP activates Gα 
which dissociates from the Gβγ dimer and triggers a Gα-specific pathway. The 
Gβγ complex can also activate a downstream pathway. Even though EP 
receptors share common signaling mechanisms however, each receptor has 
different biological effects (103, 104). All EP receptors are expressed on the 
membrane (105) with EP3 and EP4 also exhibiting nuclear membrane 
localization (106).  
EP1 receptor is a 42-kDA protein that is particularly abundant in the 
kidney and on smooth muscle associated with vessels. It has the least affinity for 
PGE2. PGE2 binding to EP1 converts GDP Gαq to GTP Gαq which then 
activates PLCβ. Upon its activation, PLCβ hydrolyzes phosphatidylinositol-4,5-
bisphosphate (PIP2)  and generates diacylglycerol (DAG) and inositol-1,4,5-
trisphosphate (IP3) which is associated with the release of CA++  from 
intracellular stores. The activation of EP1 downstream signaling alters the activity 
of many proteins including activation of PKC (107) . Studies implicate EP1 
receptor in colon carcinogenesis (108). 
EP3 receptor is unique among other EP receptors because of its 7 
alternative splicing variants defined by their C-terminal cytoplasmic tails. EP3 
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activation usually inhibits cAMP production by inhbiting adenylate cyclase via the 
activation of Gi (104). However, EP3 receptor has been shown to couple go Gi, 
Gs and Gq protein therefore, the role of EP3 receptor may vary depending on the 
cell type. 
EP2 receptor is a 53 kDa protein that upon coupling to Gs increases 
cAMP levels and activation of protein kinase A (PKA) signaling. Activation of 
cAMP/PKA pathway is associated with growth and proliferation. Phosphorylation 
of PKA activates Akt which inhibits GSK-3. Inhibition of GSK-3 relieves the 
phosphorylation of β-catenin, therefore allowing it to translocate to the nucleus, 
which results in an increase in cell proliferation (109). EP2 receptor can also 
activate proliferation by association with Axin which inactivates and releases 
GSK-3b causing β-catenin activation and translocation to the nucleus. EP2 
receptor is heavily involved in tumor development and progression in many 
organs and tissues such as breast, prostate, skin and pancreas (110, 111) (112, 
113). 
EP4 receptor also increases cAMP levels in a similar manner to EP2 
receptor. In addition to cAMP/PKA pathway, EP4 receptor activates PI3K/AKT 
signaling. Activation of EP4 receptor leads to the phorphorylation of extra cellular 
signal regulated kinases (ERKs) by PI3K (114) which activates early growth 
factor-1 (EGR-1). EGR-1 is known to regulate many genes important in cancer 
and inflammation such as PGE2 synthase, TNF-α and cyclin D1. Knock out 
studies of EP4 receptor has shown a role for EP4 in cancer and inflammation 
(115-117). 
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Targeting COX-2/PGE2 
COX-2 and PGE2 inhibition have been considered a potential 
chemotherapeutic target for pancreatic cancer. Several drugs that target COX-2 
have been developed in the past decade, the most notorious of which is the 
COX-2 inhibitor is Celecoxib. Celecoxib is a non-steroidal anti-inflammatory drug 
(NSAID) and is a highly selective COX-2 inhibitor. Traditional NSAIDs inhibit both 
COX-1 and COX-2, while celecoxib is more selective for COX-2 inhibition. COX-1 
inhibits prostaglandin and thromboxanes, while COX-2 inhibits prostaglandin 
production alone. COX-2 inhibition thus spares thromboxane without any effect 
on platelet aggregation or blood clotting. Selective inhibition of COX-2 by 
celecoxib was effective in suppressing the growth of pancreatic cancer cells in 
vitro (118) and in inhibiting tumor growth and angiogenesis in orthotopic 
implantation tumor models (119). But the treatment of pancreatic cancer patients 
with celecoxib alone or in combination with standard chemotherapeutic drugs 
was not effective in reducing the pancreatic tumor in advanced staged but also 
was highly toxic to patients (120). Patients treated with COX-2 inhibitors 
particularly, celecoxib had a high risk for heart attack and strokes. In a clinical 
trial for colon cancer prevention, patients treated with celebrex, a COX-2 
inhibitor, showed a high risk for cardiovascular diseases compared to the 
placebo (121).The toxicity behind COX-2 inhibition is mainly due to the unspecific 
inhibition of all prostaglandins. Inhibition of COX-2 causes a shift in the 
PGI2/TxA2 balance. Prostacyclin I2 (PGI2) has anti proliferative, anti aggregating 
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and vasodilating functions, whereas Thromboxane (TxA2) is a vasoconstrictor 
that has smooth muscle proliferating effects and causes platelet aggregation. 
The PGI2/TxA2 balance is essential to maintain vascular homeostasis and the 
disruption of the balance, which could be caused by COX-2 inhibition, causes 
thrombosis (122). COX-2 inhibitors have also been reported to increase blood 
pressure because of the high levels of TxA2. Therefore, emphasis has been on 
finding an alternative route to block PGE2 production, downstream of COX-2, to 
avoid the toxic side effects seen when COX-2 is inhibited. Inhibition of PGE2 
could be achieved by either increasing its inactivation by 15-PGDH or by 
targeting the inhibition of EP receptors. 15-PGDH is an enzyme that catalyzes 
the oxidation of the 15(S)-hydroxyl group of prostaglandins leading to the 
formation of metabolites with decreased activities compared to PGE2 (123), 
therefore, biologically inactivating PGE2. 15-PGDH has been shown to be a 
tumor suppressor gene that is down regulated in breast, lung, colon and bladder 
cancers (124-127). A study done in colon cancer shows that reintroducing 15-
PGDH to CD11b myeloid cells inhibits PGE2 inflammatory, immunosuppressive 
functions and increased survival. 15-PGDH inhibition of PGE2 was also 
associated with inhibition of inflammatory cytokines such as IL-6, IL-10, IL-β and 
of immunosuppressive cytokine IL-13 (128).  
An alternative way to block PGE2 production is by the inhibition of one of 
more EP receptor. As discussed previously, PGE2 exerts its actions through 
binding to one of its four receptors EP1-4. A number of studies support the role of 
each EP receptor in tumorigenesis and inflammation. Recently, EP receptors 
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have been targeted for the treatment and/or prevention of cancer.  Synthetic 
drugs, that act as antagonists or agonists for EP receptors, have been developed 
by pharmaceutical companies, and tested in vitro for their anti tumor effects 
(129). Treatment of breast cancer with an EP4 antagonist shows a reduction in 
metastasis compared to the untreated control (130). In another study done in 
colon cancer, inhibition of EP1 and EP4 receptor showed a decreased number 
and size of polyps (131). 
PGE2 and fibrosis 
COX-2 expression is considered a major factor linking chronic 
inflammation with metaplastic and neoplastic changes in pancreas (96). The 
expression of COX-2 in chronic pancreatitis was localized in the cytoplasm of 
pancreatic acinar cells, islet cells, and ductal cells but not in the surrounding 
stromal cells or infiltrating Inflammatory cells, while in pancreatic 
adenocarcinoma it was localized only to cancer cells and not to the stromal or 
inflammatory cells (92). In the pancreas the fibrotic process is associated with 
Inflammation and high levels of COX-2 activity (91, 132). COX-2 activity leads to 
increased production of the prostaglandin PGE2 at sites of inflammation in 
human tissues  (91). PGE2 has both pro-inflammatory and cell-protective 
activities, but its specific roles in pancreatic disease are unknown. PGE2 mediate 
a wide away of physiological and pathological functions in different organs and 
tissues, such as inflammation. 
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PGE2 and the tumor microenvironment 
It is now well known that the stroma surrounding the tumor cells aids in the 
development and progression of cancer. A number of tumor associated stromal 
cells express high levels of COX-2, however, not much is known on the role of 
PGE2 and its receptors in the stroma. In colon cancer, over expression of COX-2 
in the stromal cells increased the proliferation of colon cancer cells and VEGF 
production. Blocking EP4 receptor on the stromal cells blocked those effects 
completely. These results suggest that regardless of the status of COX-2 in 
cancer cells, blocking COX-2 or EP receptors could block tumor –stroma 
interactions (133). Another study done in colon cancer identifies a role for stromal 
EP4 receptor in metastasis (134). EP4 knock out in the stroma showed a 
reduction in tumor growth and metastasis. In a study done on sarcoma cells, EP3 
receptor knock out in the stromal cells reduced angiogenesis and  tumor growth, 
further supporting the role of PGE2 produced by the stroma in tumor 
development and angiogenesis (135).  Studies where EP receptors are inhibited 
and studies that target the increase of 15-PGDH (128) activity demonstrate a 
vital role for PGE2 in the stroma of tumors.  
 
Stromal PGE2 in pancreatic cancer 
The role of PGE2 in the stroma of pancreatic cancer is not fully 
understood, as only a limited number of studies have aimed to determine the role 
  
 
28 
of PGE2 in the stroma of pancreatic cancer. As discussed previously, pancreatic 
and hepatic stellate cells share many similarities and studies from hepatic stellate 
cells are used to understand the behavior of pancreatic stellate cells. In a study 
done on HSC in vitro, treatment with NS-398, a COX-2 inhibitor, reduced the 
expression of alpha smooth muscle actin, which is an activation marker for 
stellate cells.  Therefore indicating that COX-2 might play a role in the activation 
of HSC (136).  In another study, celecoxib induced HSC apoptosis through the 
inhibition of Akt activation which resulted in a reduction of fibrosis (137).  One of 
the few studies that examine the role of COX-2 in pancreatic stellate cells shows 
that COX-2 is expressed and required for PSC to respond to inflammatory 
cytokines (138). However, this study focuses more on the role of TGF-β in 
activating COX-2 expression in PSC and does not investigate the role of stromal 
COX-2/PGE2. The role of COX-2/PGE2 in the stroma of PDAC is not 
understood. There are no studies examine the role of PGE2 or its receptors in 
the regulation of stromal activation in pancreatic cancer. As mentioned 
previously, COX-2 expression is high in both chronic pancreatitis and pancreatic 
cancer which suggest that COX-2/PGE2 play a role in the regulation of 
pancreatic stellate cells, however the precise mechanism is unknown. 
 
 
 
 
  
 
29 
EXPERIMENTAL RATIONALE AND HYPOTHESIS 
 As discussed above, pancreatic ductal adenocarcinoma, also called the 
“silent killer”, is a highly lethal disease that is often asymptomatic, with a reported 
5-year survival rate of less than 5%. In western countries, PDAC is the fourth 
most common cause of cancer related death.  Currently, the therapies available 
for pancreatic cancer show only a modest increase in survival rate; patients have 
a 6 month median survival rate. A distinct feature that characterizes PDAC is the 
extensive desmoplastic reaction that surrounds the tumor. PSCs produce the 
majority of the fibrosis associated with PDAC and most lines of evidence indicate 
that PSC promote tumor development and progression. Therefore, it is clear that 
more research to understand the stroma of pancreatic cancer is needed in order 
to develop novel therapies with the hope of improving patients’ prognosis.  
 Based on the available evidence, the hypothesis for this dissertation was 
that PGE2 regulates PDAC stromal activation by increasing the activity of PSC in 
an invitro model using immortalized pancreatic stellate cells from a patient with 
pancreatic cancer. This dissertation addresses the regulation of PSC by PGE2 
and determines the receptor critical for mediating PGE2 dependent functions in 
fibrosis. In order to accomplish this, in the first aim, stromal activation in 
pancreatic cancer was “dissected” in vitro, and the effects of PGE2 on each step 
were determined by measuring changes in PSC functions. This aim assessed the 
levels of  COX-2/PGE2 produced by PSC and examined the effects of 
exogenous PGE2 on proliferation, migration, invasion potential of PSC as well as 
changes in extra cellular matrix after treatment with PGE2. 
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 The second aim of this dissertation explores the mechanism by which 
PGE2 regulates PSC, focusing primarily on determining which EP receptors are 
involved in mediating PSC activity by PGE2 and what signaling pathways 
activated downstream of PGE2 in PSC. In addition, this aim addresses 
modulation of PSC “fibrotic” functions by blocking EP4 receptor activity in vitro to 
determine the role of EP4 as a potential therapeutic target. 
 The third aim of this dissertation examines the mechanisms of PGE2 on 
stromal activation in pancreatic cancer at the molecular level by determining the 
EP4 dependent downstream signaling pathways activated and by determining 
the role of PGE2 in regulation Collagen I, focusing on the expression and 
transcriptional activity of Collagen I gene. This aim also determines the role of 
blocking EP4 receptor on Collagen I gene. The last part of this chapter aimed at 
identifying the area in the promoter of collagen I regulated by PGE2.  
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CHAPTER TWO: PROSTAGLANDIN E2 REGULATES THE ACTIVATED 
PHENOTYPE OF PANCREATIC STELLATE CELLS 
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INTRODUCTION 
 
 Pancreatic fibrosis is the formation or development of excess fibrous 
connective tissue in pancreas as a reparative or reactive process (139). The 
hallmark of chronic pancreatitis and pancreatic cancer is pancreatic fibrosis. It is 
the inflammation of the pancreas. Inflammation is associated with a high increase 
of COX-2 activity (140) .COX-2 activity leads to increased production of the 
prostaglandins PGE2 at sites of inflammation in human tissues. PGE2 has both 
pro-inflammatory and cell-protective activities. COX-2 and PGE2 are correlated 
with worse prognosis in many cancers like lung, gastric and pancreas (141).   
Prostaglandin endoperoxide synthase, commonly referred to as 
cyclooxygenase (COX), catalyzes the double oxygenation and reduction of 
arachidonic acid (AA), after its release from membrane glycerophospholipids by 
phospholipase A2 (PLA2), to the intermediate form prostaglandin H2 (142) which 
is further metabolized to form prostaglandin E2 catalyzed by microsomal PGE2 
synthases (143). Currently, there are three known COX isoforms COX-1, COX-2 
and COX-3 (a splice variant of COX-1). COX-1 is a ubiquitously and 
constitutively expressed isoform that is postulated to have “housekeeping” 
functions with basal production of prostaglandins under homeostatic conditions. 
In contrast, COX-2 is encoded by an early-response gene and can be rapidly 
induced by growth factors, cytokines, inflammatory mediators and tumor 
promoters (144). By immunohistochemistry (IHC), COX-2 was found to be highly 
expressed in chronic pancreatitis (91), pancreatic adenocarcinoma (92-95) and 
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pancreatic intraepithelial neoplasia (PanIN) (145). The expression of COX-2 in 
chronic pancreatitis was localized in the cytoplasm of pancreatic acinar cells, islet 
cells, and ductal cells but not in the surrounding stromal cells or infiltrating 
inflammatory cells (91), while in pancreatic adenocarcinoma also it was localized 
only to cancer cells and not to the stromal or inflammatory cells (92)  .COX-2 
overexpression is an established factor linking chronic inflammation with 
metaplastic and neoplastic changes in pancreas (96). Transgenic over-
expression of COX-2 in the pancreas has been shown to lead to the 
development of pancreatic fibrosis (96). Despite the correlation between COX-2 
and fibrosis, the mechanisms involved in COX-2 mediated stromal activation in 
pancreatic cancer are unclear.   
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) and is a 
highly selective COX-2 inhibitor. Traditional NSAIDs inhibit both COX-1 and 
COX-2, while celecoxib is more selective for COX-2 inhibition. COX-1 inhibits 
prostaglandin and thromboxanes, while COX-2 inhibits prostaglandin production 
alone. COX-2 inhibition thus spares thromboxane without any effect on platelet 
aggregation or blood clotting. Selective inhibition of COX-2 by celecoxib was 
effective in suppressing the growth of pancreatic cancer cells in vitro (146) and in 
inhibiting tumor growth and angiogenesis in orthotopic implantation tumor models 
(119). But the treatment of pancreatic cancer patients with celecoxib alone or in 
combination with standard chemotherapeutic drugs was highly toxic to patients 
(120). 
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Stellate cells are resident cells of the pancreas, located at the basolateral 
aspect of acinar cells (147). In the normal pancreas, stellate cells are quiescent, 
identifiable by the presence of vitamin-A containing lipid droplets in the cytoplasm 
and positive immunostaining for cytoskeletal proteins such as desmin and glial 
acidic fibrillary protein. In health, PSC play a role in extracellular matrix turnover 
via their ability to synthesize matrix proteins as well as matrix-degrading 
enzymes, MMPs. During necroinflammatory injury, PSC become activated and 
assume a myofibroblast-like phenotype characterized by the loss of vitamin A 
droplets, the production of a-SMA and extracellular matrix proteins such as 
collagen I and III, fibronectin and laminin (148). Factors known to be upregulated 
during pancreatic injury such as TGF-b, platelet-derived growth factor (PDGF) 
and proinflammatory cytokines, stimulate PSC proliferation and production of 
extracellular matrix proteins (149). Notably, activated PSC also produce 
increased amounts of matrix metalloproteinase-2 (MMP2) (69), known to 
degrade collagen IV, an essential component of the basement membrane, 
thereby facilitating the deposition of fibrillar collagen1a as observed in pancreatic 
fibrosis. But, the exact mechanisms regulating stellate cells and their 
development of pancreatic desmoplasia are not fully understood. 
 In the current study, I sought to further understand the role of PGE2 on 
stromal activation in pancreatic cancer in vitro using human pancreatic stellate 
cells from a patient with PDAC. I determined that PGE2 might be a useful target 
for novel therapies and that targeting prostaglandin pathways may be a strategy 
to interfere with stromal activation in pancreatic cancer. Hence, I have 
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investigated the effects of PGE2 on pancreatic stellate cells.  As a measure to 
study stromal activation in pancreatic cancer, primary human pancreatic stellate 
cells (PSC) from a patient with pancreatic cancer, were isolated and immortalized 
as mentioned in  previous publications (68). These studies showed that, PSCs 
cells express COX-2 and secrete PGE2 and PGE2 has autocrine effects on 
stellate cells. Exogenous addition of PGE2 on PSC stimulated the migration and 
invasion of stellate cells and also production of extra cellular matrix (ECM) 
proteins – fibronectin, collagen 1a, HSPG2, vimentin and elastin; and production 
of matrix metalloproteinases (MMP) – 2 & 9. Thus, this study provides a better 
understanding on regulation of stellate cells by PGE2 and further the role of 
stellate cells on pancreatic stromal activation in pancreatic cancer. This study 
suggests that PGE2 could be an alternative potential therapeutic target to reduce 
COX-2 mediated stromal hyperactivation associated with chronic pancreatitis and 
pancreatic cancer. 
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MATERIALS AND METHODS 
 
Materials 
Culture media and fetal bovine serum (FBS) were obtained from Life 
Technologies, Inc. (Rockville, MD). PGE2, was obtained from Cayman 
Chemicals. 
 
Cell Culture 
Primary human pancreatic stellate cells (PSC) were isolated using the outgrowth 
method from pancreatic adenocarcinoma samples from patients undergoing 
surgical resection and were immortalized (68)(Hwang RF, 2008). PSCs were 
maintained at 37°C in a humidified atmosphere of 5% CO2 and were grown in 
10% DMEM containing 1% antibiotic. PGE2 was purchased from Cayman 
Chemicals (Ann Arbor, MI).  
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Invasion and Migration assays 
 
For studies of cell invasiveness, BIOCOAT Matrigel invasion chambers (BD 
Biosciences, Chicago, IL) were used. Briefly , 2 x 105 cells in 100 ul of serum-free 
medium were added to the upper chamber and different concentrations of PGE2 
(1–1000 nM) in 0.5% serum containing DMEM were added into the lower 
chamber. The cells were allowed to invade the Matrigel for 22 h at 370C in a 5% 
CO2 atmosphere. DMEM containing 0.5% serum was used as control. The non-
invading cells on the upper surface of the membrane were removed with a cotton 
swab and the invading  
\cells on the lower surface of the membrane were fixed and stained with a Diff-
Quick stain kit (BD Biosciences), washed twice with water and air-dried. Invading 
cells in three adjacent microscope fields for each membrane were imaged at 20x 
magnification. To assess cellular migratory potential, the protocol described 
above was used, except that migration chamber devoid of matrigel was used (BD 
Biosciences, Chicago, IL). Experiments were performed at least in triplicate, and 
the results were shown as mean ± SD of three independent experiments 
 
MTS proliferation assay 
 
 MTS was obtained from Promega. MTS is a tetrazolium salt that undergoes a 
color change caused by its bioreduction of MTS into a water-soluble formazan. 
  
 
38 
The conversion of MTS into the aqueous-soluble formazan is accomplished by 
dehydrogenase enzymes found in active mitochondria and is such that the 
reaction occurs only in living cells. The quantity of formazan product measured 
by the amount of 490-nm light absorbance is directly proportional to the number 
of living cells in culture. MTS (2 mg/ml; pH 6.5) was dissolved in PBS and filter 
sterilized. A 3-mM PMS solution was also prepared (in PBS) and filter sterilized. 
These solutions were stored at −20°C in light-protected containers. MTS (100µ l) 
was added to each well. After incubation at 37°C in a humidified atmosphere with 
5% CO2 for 1 hours, the optical density was measured at 490 nm by means of 
spectrophotometry. Cell growth was analyzed by means of MTS assay after 0, 
24, and 48 hours of culture. Cell proliferation was analyzed with a 
hemocytometer and a cell counter (Coulter, Hialeah, FL). 
 
Apoptosis detection 
 
 To define the level of apoptosis, PSC cells were trypsinized, pelleted, fixed, and 
propidium iodide (PI) stained. Propidium iodide fluorescence activated cell 
sorting analysis (PI-FACS). Cells were seeded onto 6-well plates at 2x106 
cells/plate. The next day, media was aspirated and replaced with low serum 
0.5% FBS containing media. After 24 hours of starvation, PSC were treated with 
PGE2 (50 or 100 nM) or DMSO for 24 hrs. Twenty four hrs after PGE2 treatment, 
media and cells were collected and fixed in 75% cold ethanol. Cells were stained 
with PI (50 µg/ml) and analyzed by flow cytometry (Beckman Coulter, Inc). 
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Reverse transcription-PCR 
 
 Total RNA was isolated from PSC with and without siRNA transfection and the 
quality of RNA was tested as mentioned previously. DNAse was used to remove 
contaminating genomic DNA and RNA purification. Quality of the RNA was 
confirmed by running on a denaturing gel, and we have observed clear 28S and 
18S rRNA bands. A non reverse transcribed control was used to assure that no 
genomic DNA was amplified.  Primers were designed for human   
MMP-2 (5’ CTTCTTGTCGCGGTCGTAGTCCTC3’) (3’ 
TGGCGATGGATACCCCCTTGA5’) ,  
MMP-9 (5’ GCGCTGGGCTTAGATCATTCCTCA 3’) (3’ 
GCAGCGCGGGCCATTGTC 5’) ,  
MMP-1 (5’ ATTCTACTGATATCGGGGCTTTGA3’) (3’ 
TGTCCTTGGGGTATCCGTGTGTAG5’) ,  
MMP-7 (5’ AAACTCCCCGCGTCATAGAAATAAT 3’) (3’ 
TGAGTTGCAGCATACAGGAAGTT 5’),  
MMP-11 (5’ CTGGCGGGCGCTGGGAGAAGAC 3’) (3’ 
CAGGGCTGGCCATATAGGTGTTGA5’),  
TIMP-1 (5’ CGTCATCAGGGGCCAAGTTCGTG 3’) (3’ 
GAGGCAGGCAGGCAAGGTGAC 5’),  
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TIMP-2 (5’CTGGCGGGCGCTGGGAGAAGAC3’) 
(3’CAGGGCTGGCCATATAGGTGTTGA3’)  
Fibronectin (5’ CCGCCACGTGCCAGGATTACC 3’) (5’ 
AGGGGCTCGCTCTTCTGATTATTC 3’) ,  
Vimentin (5’ GGTCCGTGTCCTCGTCCTCCTAC 3’) (3’ 
CGCGGGCTTTGTCGTTGGTTA 5’) ,  
Elastin (5’ GGACCCCTGACTCACGACCTC 3’) (5’ 
ACTTGGCCGCTCCCCTCTTGTTTC 3’),  
HSPG2   (5’ CCGCCAGGGCAGGTCA 3’) (3’ 
GGTGGGCAGCGGTAGGAAGGAGTA 5’),  
COX-2 (5’GGTCTGGTGCCTGGTCTGATGATG3’) (5’ 
GTCCTTTCAAGGAGAATGGTGC 3’).  
The amplified products were separated on 1.5% agarose gels and visualized by 
ethidium bromide. Primers designed for β-actin (Genbank BC_016045), which 
was used as a loading control for the PCR reactions, were forward 5' ATG ATA 
TCG CCG CGC TCG TCG TC 3' and reverse 5' CGC TCG GCC GTG GTG GTG 
AA 3'. 
 
Immunohistochemical Staining for COX-2 
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 Unstained 4uM tissue sections from human patients were deparaffinized with 
xylene and rehydrated with ethanol. Endogenous peroxidase activity was blocked 
with 3% hydrogen peroxide in methanol and non specific binding sites were 
blocked with protein blocking solution (5% normal horse and 1% normal goat 
serum). Primary antibody against COX-2 (1:800 dilution; cat # HPA001335 ) was 
added and the samples were incubated overnight at 4°C. The secondary 
antibody was added and incubated for 1 hour at room temperature. Finally, slides 
were developed with 3,3 diaminobenzidine substrate (DAB) and counterstained 
with hematoxylin. Then the slides were dehydrated with ethanol, fixed with xylene 
and mounted. Immunohistochemistry was analyzed using an inverted light 
microscope (Olympus, Center valley, PA). Images were captured using a chilled, 
charge coupled device camera (Hamamatsu, Bridgewater, NJ) and smartcapture 
software (Digital Scientific, Cambridge, UK).  
 
Statistical analysis 
All experiments were conducted in triplicates and carried out on three or more 
separate occasions. Data presented are means of the three of more independent 
experiments +/- standard error mean (SEM). Statistical analysis was done using 
GraphPad Prism (GraphPad Software). Comparisons were made using two-tailed 
Student's t test and significant difference was defined as P < 0.05. Data are 
shown as mean ± SE.  
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RESULTS 
 
COX-2 is overexpressed in PDAC and PSC produce high levels of PGE2 
The immunohistochemical analysis of COX-2 expression in tissue sections from 
pancreas resected from human pancreatic tumors showed high levels of staining 
intensity of COX-2 compared to normal pancreas tissues (Figure 2.1.1). PDAC 
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showed high patterns of expression from low staining to high staining. In order to 
determine whether COX-2 plays a role in the pancreatic stroma, I examined if 
PSC express COX-2. mRNA was amplified from immortalized PSCs (line 1 and 
2) and RT-PCR showed that all PSC examined express COX-2 (Figure 2.1.2). 
Furthermore, to determine whether PGE2 is secreted by the PSCs, I quantified 
the levels of PGE2 both intracellularly and media bathing the stellate cells. I 
employed Liquid Chromatography- tandem mass spectrometry, which is able to 
distinguish geometrical isomers and accurately measure levels of different 
prostaglandins produced.  PGE2 had an intracellular concentration of 20 ng/ml, 
being the highest among all other ecosanoids examined. Even at the secreted 
levels of ecosanoids, PGE2 levels were the highest among the prostaglandins 
examined (260 ng/ml) (Figure 2.1.3).  PGE2 was found in the media bathing the 
cultured PSCs, indicating that this mediator is released by the PSCs into the 
microenvironment.  This data indicates that PGE2 is highly present and produced 
by PSC. It is already known that PGE2 are secreted by pancreatic cancer cells. 
Therefore, there are at least two potential sources that account for the production 
of PGE2 in the stroma. This also suggests that PGE2 plays a role in the 
regulation of the tumor microenvironment and not only the cancer cells. 
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3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Ecosanoid levels in PDAC and PSC (1) Human tissue sections 
were immunostained for COX-2 and their respective serial sections with H&E. 
IgG was used as a control and showed no immunoreactivity (data not shown). 
COX-2 expression was not detected in the sections containing normal pancreas. 
In cancer sections, COX-2 is upregulated when compared to the normal 
pancreas and positive staining in found in the ductal compartment of the 
pancreas (x400 magnification).(2) RT-PCR showing the expression of COX-2 in 
PSC.(3)Liquid Chromatography tandem mass spectrometry showing the levels of 
ecosanoids intracellularly;cell pellet was collected and subjected to LC MS MS to 
determine the concentration of ecosanoids. The media bathing PSC was 
collected and subjected to LC MS MS to determine the levels of ecosanoids 
extracellularly.   
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PGE2 stimulates migration, invasion in PSC 
  
To determine the effects of PGE2 on the functions of stellate cells, I 
looked at phenotypic changes in PSCs caused by PGE2 treatment in vitro. First, 
the migration potential of PSCs was assessed using a conventional Boyden 
Chamber assay, with the control or PGE2 in different concentration was added to 
the bottom chambers to determine if PGE2 acts as a chemoattractant that 
induces PSC migration. I treated PSCs with PGE2 in vitro. PSC re-suspended in 
0.5% serum containing media (2x104) was plated on migration chambers with 
and without PGE2 (0-1000nM).  After 22hrs, cells migrated to the bottom side of 
the chamber were fixed with methanol and stained with hematoxylin and number 
of cells migrated or invaded was counted on at least 10 fields looking under the 
microscope. Exogenous addition of PGE2 induced a dose dependent significant 
increase in PSC cell migration (Figure 2.2) in vitro with an optimal concentration 
being 100nM of PGE2.  Next, I looked at the effects of PGE2 on the invasion 
potential of PSC and its ability to penetrate through Matrigel, using a modified 
Boyden Chamber assay. PSCs were plated at a confluency of 2x104 cells per 
well (upper chamber) after being incubated in near starvation conditions (0.5% 
serum containing media) for 24 hours. The bottom chambers contained different 
concentrations of PGE2 or the vehicle. 10% FBS was used as a positive control. 
After 22hrs, cells invaded through the matrigel matrix to the bottom side of the 
chamber were fixed with methanol and stained with hematoxylin and number of 
cells invaded was counted on at least 10 fields looking under the microscope. 
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The wells that did not have PGE2 showed no PSC invasion. However, PGE2 
increase PSC invasion at concentrations ranging from as little as 25nM of PGE2 
to 1000nM PGE2 after 22 hours (Figure 2.3). The maximum invasive effects 
were detected at 100nM PGE2. Therefore, PGE2 stimulates both PSC migration 
and invasion in a dose dependent manner compared to the untreated control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
49 
 
 
 
 
 
 
Figure 2.2 Effects of PGE2 on PSC migration PSC migration was evaluated 
using a Boyden chamber assay. PSC (20 x 103 cells/well) were plated in the 
upper Boyden Chamber in serum free media. The lower wells contained 
0,10,25,50,100,500,1000nM) of PGE2. Cells were stained with H&E and the 
number of cells  migrated was calculated. PSC stimulated with PGE2 for 6 hours 
(data not shown  *, P<0.05   
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Fig
ure 
2.3 
Eff
ect
s of 
PG
E2 
on 
PS
C invasion PSC invasion was assessed by modified Boyden chamber assay. 
PSC (20 x 103 cells/well) were plated in the upper chamber of the apparatus and 
different concentrations of PGE2 were added to the lower chambers. Cells were 
stained by H&E and cell invasion through matrigel was calculated. P<0.05 versus 
control. 
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PGE2 stimulates changes in PSCs gene expression 
 
 In order to see if stimulation of PSC with high levels of PGE2 affects 
stromal gene expression, PSCs were incubating in 0.5% serum containing media 
for 24 hours for serum starvation, next RNA was extracted from PSC treated with 
PGE2 (100nM) and control treated with the vehicle (DMSO) and converted to 
cDNA. Using RT-PCR with specific primers for each gene, I looked at changes in 
the expression of the following genes: HSPG2, vimentin, fibronectin and elastin 
(Figure 2.4.1) which are known to be involved in fibrosis and were found in 
microarray studies from our laboratory to be high in the stroma, therefore called 
“stromal genes”.  This data shows that PGE2 addition to PSCs stimulated the 
expression of the above mentioned genes therefore indicating the stimulatory 
effects of PGE2 on stromal gene expression.  
To further investigate the role of PGE2 in PSCs activation, changes to the 
expression pattern of genes involved in matrix turnover were assessed. I looked 
at changes in the expression of a panel of MMPs and TIMPs after PGE2 
treatment compared to the untreated control (Figure 2.4.2).  I found that PGE2 
addition, increases PSC gene expression of MMP-2, MMP-3, MMP-9, and TIMP-
1 whereas the expression of MMP-11 and TIMP-2 remained unchanged. 
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Figure 2.4 Effects of PGE2 on PSC gene expression: (1) RT-PCR showing 
the expression of HSPG2,Elastin,Fibronectinm,Vimentin before and after 
stimulation with PGE2. 100nM PGE2 was added to PSC after over night serum 
starvation and left for 24 hours. B-actin was used as a control.(2) RT-PCR the 
expression of MMP-2, 3, 9, 11 and TIMP-1,2  before and after stimulation with 
PGE2. 100nM PGE2 was added to PSC after over night serum starvation and left 
for 24 hours. B-actin was used as a control. *, P<0.05   
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PGE2 stimulates the proliferation of PSC 
 
To examine the role of PGE2 on PSC proliferation and growth, PSC were 
incubated in near starvation conditions for 24 hours and treated with PGE2 in 
doses ranging from 10nM to 1000nM. As a negative control, the vehicle for 
PGE2, DMSO was added to PSC separately. PSC proliferation was analyzed by 
means of a non radioactive MTS assay after 0, 24, 48 hours of PGE2 treatment.  
PGE2 addition to PSC induced an increase in proliferation seen at 100nM PGE2 
added for 24 hours (Figure 2.5). Results were confirmed by the cell counter and 
hemocytometer proliferation assays (data not shown here).There was no 
significant different between addition of PGE2 for 24 hours or 48 hours (data not 
shown). 
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Figure 2.5 Effects of PGE2 on PSC Proliferation PSC proliferation was 
measured by MTS assay. PSC (1000 cells) were plated on a 96-well plate and 
serum starved overnight. PGE2 (10,100,500 nM) were exogenously added to the 
plates and estimated after 24 hours by MTS assay. PGE2 stimulates the 
proliferation of PSC*, P<0.05   
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PGE2 did not affect PSC apoptosis 
 
To determine the effects of PGE2 on PSC apoptosis, I looked at PGE2 
induced PSC apoptosis by propidium iodide (PI) staining.  I analyzed by FACS 
the level of apoptosis of PSC treated with 0, 50 and 100nM PGE2 over 24 and 48 
hours (data for 48 hours is not shown). The percentage of PSC stained with PI 
and analyzed by FACS did not change when PGE2 was added to the cells, 
therefore PGE2 did not affects the apoptosis level of PSC (figure 2.6).  No effects 
of PGE2 treatment was observed on the fraction of the cells underdoing DNA 
synthesis stage of the cell cycle (data not shown). 
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Figure 2.5. Effects of PGE2 on PSC survival and apoptosis PSC apoptosis 
and survival was assessed by FACS analysis and PI staining. PSC were treated 
with 0 and 100 nM PGE2 for 24 hours and subjected to propidium iodide staining. 
Representive experiment is shown. Statistics were perfomed as described in 
methods. No statistical difference between PGE2 treated cells and the negative 
untreated control. *, P<0.05   
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DISCUSSION 
 
PSCs have recently become the focus of much attention due to their 
importance in PDAC.  However, these cells also play a critical role in CP.  In both 
diseases PSCs become activated and produce an abundant desmoplastic 
response. Many factors are known to regulate PSC activity including regulatory 
molecules such as TGFb, PDGF, CTGF and others. Studies have shown that 
addition of TGFb results in an increase in PSC activation and subsequent 
increase in contractility, matrix degradation, proliferation and MMP and TIMP 
production(150, 151)  Furthermore, studies have shown that COX-2 is high in 
both CP and PDAC therefore suggesting a potential role in stromal 
hyperactivation related associated with PDAC. Many studies have shown that 
COX-2 levels positively correlates with the aggressiveness of PDAC (141) (96) 
and that blocking COX-2 (152) significantly reduces the tumor size and 
metastatic potential. There have been suggestions that the activity of COX-2 and 
prostaglandins influence PSC (153). However, the role of COX-2 and PGE2 has 
not been fully assessed in the stroma of PDAC. This study aimed at identifying 
the functional role of COX-2 and its downstream effector PGE2 in the stroma, 
particularly by examining PGE2 dependent alterations in the profibrogenic 
phenotype of PSC. I have dissected the stromal hyperactivation related 
associated with PDAC into five major responses that contribute to the 
development of the fibrogenic phenotype that follows quiescent PSC activation in 
response to inflammation; proliferation, migration, penetration (invasion), 
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alteration of matrix composition (over expression of stromal genes) and 
apoptosis. A major aspect of fibrosis is the changes in extra cellular matrix 
composition. During fibrosis, the matrix composition shifts from a normal matrix 
rich in collagen IV rich basal lamina to a fibril forming collagen I. These findings 
show that upon stimulation with PGE2 serum starved PSC highly increase their 
expression of several genes involved in matrix formation such as HSPG2, 
fibronectin and elastin. Matrix MetalloProteases (MMPs) are also involved in 
fibrosis, particularly MMP-2 and MMP-9. MMP-2’s primary function is the 
degradation of Collagen IV.  The following step in the fibrotic cascade is the 
migration of PSC to the newly formed basement membrane rich in collagen I and 
the penetration, or invasion through the matrix. Our data show a timely increase 
in both PSC migration and invasion following stimulation with PGE2. MMP-2 and 
MMP-9 degrade the extra cellular matrix thereby facilitating the penetration of the 
cells through the basement membrane. Our data also show that PGE2 increases 
the expression of MMP-2 and MMP-9 in serum starved PSC. PGE2 mildly 
stimulated the proliferation of PSC, however, the role of proliferation in already 
activated PSC is debatable. It has been suggested that stellate cells that make 
up the fibrotic reaction do not all derive from quiescent stellate cells. Stellate cells 
also derive from bone marrow and epithelial mesenchymal transitions(154) . 
 
 Until now the specific effects of prostaglandins on PSC has not been 
identified.  I observed that there are several potential sources of prostaglandins 
within the microenvironment of PDAC including PDAC cells as well as PSC 
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themselves.  I also found that PGE2 stimulated PSC functions including 
migration, proliferation, invasion and  expression of genes such as MMPs and 
TIMPs which are likely to determine whether fibrosis recedes or procedes (155, 
156).    
This study also examined the role of PGE2 in apoptosis of PSC. I found 
that PGE2 does not stimulate apoptosis of PSC. Furthermore, treatment with 
PGE2 caused an increase in cell proliferation. The importance of PSC- PDAC 
has recently been the focus of many studies. Recent studies have shown that 
PSC promoted the progression of PDAC (157). The co injection of PSC and low 
numbers of PDAC cells in a nude mouse model resulted in 100% tumor 
incidence, as opposed to 57% when the cancer cells were injected alone. 
Although the role of importance of the stroma in PDAC is well known, the 
molecular mechanisms that regulate stromal activity and the downstream 
signaling involved are poorly understood. This study provides evidence for the 
first time that PGE2 can induce major changes in the “fibrogenic response” 
associated with PDAC and CP. These changes include contribution to the 
formation of the “fibrotic” matrix by changing its composition, migration, invasion 
as well as changes in gene expression. Therefore, prostaglandin E2 is 
responsible for inducing pro fibrogenic changes in pancreatic stellate cells.   
Furthermore, it has been shown that TGF-b secreted by the cancer cells 
activates quiescent stellate cells. (158) Candidate genes that mediate tumor 
stroma interactions have been identified by gene expression profiling. 
Cyclooxygenase-2 (COX-2) was one of the genes that was found to be high in 
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both PDAC and CP. Studies have shown the COX-2 pathway to be an important 
target in the treatment and prevention of many cancers including pancreatic 
cancer (159). A study done has shown COX-2 gene and its primary and most 
important metabolite prostaglandin E2 (PGE2) to be expressed in over 90% of 
pancreatic (160) suggesting that COX-2 maybe a target for chemoprevention and 
treatment of PDAC. Many studies support this theory, however, the limited 
success of COX-2 inhibitors in the clinic mainly because of the cardiovascular 
and renal side effects (152, 161), urges us to look for a more specific target in the 
COX-2 pathway.  
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CHAPTER THREE: EP4 RECEPTOR IS REQUIRED FOR PGE2 MEDIATED 
PSC HYPERACTIVITY 
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INTRODUCTION 
Pancreatic cancer is the fourth leading cause of cancer related death in 
the U.S. Currently no effective treatments for PDAC and the dense desmoplasia 
surrounding it exist. The prognosis of PDAC is dismal with a 5 year survival rate 
of 5%. The dense desmoplastic reaction around the tumor mass is a major 
characteristic of pancreatic cancer. Numerous reports in the literature suggest 
that the tumor-stroma interactions in the pancreas contribute to progression and 
metastasis. Until now, the focus has been on identifying therapy potentials that 
targeting the actual tumor disregarding the importance and contribution of the 
stroma. No therapies against pancreatic desmoplasia are available. Numerous 
reports had shown that cyclooxygenase-2 (COX-2) was upregulated in the 
majority of pancreatic cancer patients (92), this over expression was also 
associated with advanced tumour stage and correlates with poor prognosis. In 
the pancreas, the fibrotic process is associated with inflammation and high levels 
of COX-2 activity.  Microarray data from our laboratory identify COX-2 gene as 
one of the genes that might play a role in stromal hyperactivation. COX-2 levels 
were low in normal pancreas tissue however; COX-2 levels increase in chronic 
pancreatitis and increase further more in PDAC samples therefore, suggesting a 
role of COX-2 in the fibrotic compartment of PDAC. Treatment with NSAIDs like 
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celecoxib, which block COX-2 activity have shown efficient reduction of 
tumorigenicity in vitro. Furthermore, pancreatic cancer patients treated with 
selective COX-2 inhibitors have presented significant reduction in tumor size and 
increased survival. While many studies confirm the chemopreventive effects of 
COX-2 inhibitors, the side effects caused by long term therapy with COX-2 
inhibitors  such as cardiovascular and renal events are even clearer (118, 
120, 146).  
The chemopreventive and anti tumorigenic functions of NSAIDs are due to 
their inhibition of prostaglandin synthesis by COX mostly, PGE2. PGE2 has been 
reported to the COX-2’s most biologically active product. Most of COX-2 
functions have been attributed to PGE2. In humans, four receptors called EP 
receptors have been identified as mediators of PGE2 activity. EP1,2,3 and 4 are 
localized to the plasma membrane and the binding of PGE2 to each receptor 
activates specific downstream signaling pathways (162).  
EP1 receptor binds a G-protein which increases intracellular Ca2+ levels 
and IP3 levels. EP2 and EP4 receptors are Gs protein–linked that increase cyclic 
AMP (cAMP), on the other hand, EP3 receptor is Gi linked and blocks cAMP 
increase. Therefore, the effects of PGE2 greatly depend on downstream 
signaling that starts with second messenger response (104). Recently, studies 
have shown that EP receptors play a role in colon carcinogenesis (163) and in 
carcinomas of endometrial, breast, and lung (113, 135, 164). 
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Despite of the importance of EP receptors in cancer progression and even 
though EP-2 receptor has been identified to be crucial for pancreatic cancer 
cells, the role EP receptors in pancreatic desmoplasia or PSC biology has not 
been identified. PGE2 modulates a wide array of biological functions essential to 
tumor growth, progression and survival (90, 165, 166). Therefore, there is a 
strong rationale to understand the mechanisms behind PGE2 functions and the 
downstream targets of COX-2/PGE2. Selective COX-2 inhibitors have shown 
great promise in treating pancreatic cancer but their adverse side effects are not 
suitable for long term use (121, 167) therefore, it is clear that the attention must 
shift from focusing on COX-2/PGE2 to targeting more downstream effectors such 
as EP receptors as a potential therapeutic target. Based on these findings, I 
sought to determine the functional role of EP receptors on the stromal 
compartment of pancreatic cancer in vitro by looking at the biology of PSC.  
The aim of this study was to identify the functional role of each EP 
receptor in mediating PGE2 dependent stimulation of PSC. I examined the 
mechanism behind PGE2 stimulation of PSC activity by silencing each receptor 
to identify the role each plays in mediating the changes inflicted by PGE2. 
Furthermore, I explored blocking EP receptors by treating PSC with specific 
antagonists against each receptor and measured changes in migration, invasion 
and gene expression. This study uses two different approaches to identify the 
functional role of each receptor in PSC biology; siRNA silencing and receptor 
antagonism. The results of this study were very promising as blocking only EP4 
receptor resulted in a dramatic reduction of PSC activity to a near basal level. In 
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this study, I have identified for the first time the receptors that mediate the effects 
of PGE2 on pancreatic stellate cells. By siRNA mediated silencing, I have 
identified EP4 as the receptor responsible for PGE2 mediated effects on PSCs. 
Knowledge of the roles of the specific receptors will aid in the identification of 
appropriate targets for therapeutic development against pancreatic fibrosis. Thus, 
this study provides a better understanding on regulation of stellate cells by PGE2 
and further the role of stellate cells on pancreatic stromal hyper stimulation. This 
study also identifies EP4 as a mediator of PGE2 activity that is required for PSC 
hyper activation therefore, EP4 could be an alternative potential therapeutic 
target to reduce COX-2 mediated fibrosis associated with chronic pancreatitis 
and pancreatic cancer. 
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MATERIALS & METHODS 
 
Materials 
 Culture media and fetal bovine serum (FBS) were obtained from Life 
Technologies, Inc. (Rockville, MD). PGE2, was obtained from Cayman 
Chemicals. 
  
Cell Culture 
Primary human pancreatic stellate cells (PSC) were isolated using the outgrowth 
method from pancreatic adenocarcinoma samples from patients undergoing 
surgical resection and were immortalized (68) (Hwang RF, 2008). PSCs were 
maintained at 37°C in a humidified atmosphere of 5% CO2 and were grown in 
10% DMEM containing 1% antibiotic. PGE2, EP1 antagonist (cat # SC18220) 
and EP2 antagonist (cat # AH 6809) were purchased from Cayman Chemicals 
(Ann Arbor, MI). The EP4 antagonist (ONOAE3208) was obtained  from ONO 
pharmaceuticals (Osaka, Japan).  
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Invasion and Migration assays 
 
 For studies of cell invasiveness, BIOCOAT Matrigel invasion chambers (BD 
Biosciences, Chicago, IL) were used. Briefly , 2 x 105 cells in 100 ul of serum-free 
medium were added to the upper chamber and different concentrations of PGE2 
(1–1000 nM) in 0.5% serum containing DMEM were added into the lower 
chamber. The cells were allowed to invade the Matrigel for 22 h at 370C in a 5% 
CO2 atmosphere. DMEM containing 0.5% serum was used as control. The non-
invading cells on the upper surface of the membrane were removed with a cotton 
swab and the invading cells on the lower surface of the membrane were fixed 
and stained with a Diff-Quick stain kit (BD Biosciences), washed twice with water 
and air-dried. Invading cells in three adjacent microscope fields for each 
membrane were imaged at 20x magnification. To assess cellular migratory 
potential, the protocol described above was used, except that migration 
chambers devoid of matrigel was used (BD Biosciences, Chicago, IL). 
Experiments were performed at least in triplicate, and the results were shown as 
mean ± SD of three independent experiments 
 
Reverse transcription-PCR 
 Total RNA was isolated from PSC with and without siRNA transfection and the 
quality of RNA was tested as mentioned previously. DNAse was used to remove 
contaminating genomic DNA and RNA purification. Quality of the RNA was 
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confirmed by running on a denaturing gel, and we have observed clear 28S and 
18S rRNA bands. A non reverse transcribed control was used to assure that no 
genomic DNA was amplified.  Primers were designed for human   
EP1 (5’ ATCGCTTCGGCCTCCACCTTCTTT 3’) (3’ 
GCCAGCGCCACCAACACCA 5’),  
EP2 (5’ CTCGCTGCCGCTGCTGGACTATGG 3’) (3’ 
GCAGGCGAGCACCGAGACAATGAG 5’),  
EP3 (5’ GGCGCTGGCGATGAACAACGAG 3’) (3’ 
GGCGCTGGAGATGAACAACGAG 5’),  
EP4 (5’ CCGCCCCCAGGTAGCCAGGAG 3’) 
(3’TGCGGGAGGACAGCGTTCAGGT 5’),  
MMP-2 (5’ CTTCTTGTCGCGGTCGTAGTCCTC3’) (3’ 
TGGCGATGGATACCCCCTTGA5’) ,  
MMP-9 (5’ GCGCTGGGCTTAGATCATTCCTCA 3’) (3’ 
GCAGCGCGGGCCATTGTC 5’) , 
The amplified products were separated on 1.5% agarose gels and visualized by 
ethidium bromide. Primers designed for β-actin (Genbank BC_016045), which 
was used as a loading control for the PCR reactions, were forward 5' ATG ATA 
TCG CCG CGC TCG TCG TC 3' and reverse 5' CGC TCG GCC GTG GTG GTG 
AA 3'. 
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Transient transfection of small interfering RNA 
 PSC was plated on 100-mm dishes and transiently transfected with siRNAs-
siControl (siRNA ID  #4611 Ambion INC Austinm TX) and siEP2 and EP4 (siRNA 
IDs # 5732, # 5734, Qiagen, Valencia, CA) at a final concentration of 10 nmol/L 
(Dharmacon, Inc.) with Hiperfect transfection reagent (Qiagen, Inc.), and lysates 
were prepared for RT-PCR after 72 h. 
 
Statistical analysis 
All experiments were conducted in triplicates and carried out on three or more 
separate occasions. Data presented are means of the three of more independent 
experiments +/- standard error mean (SEM). Statistical analysis was done using 
GraphPad Prism (GraphPad Software). Comparisons were made using two-tailed 
Student's t test and significant difference was defined as P < 0.05. Data are 
shown as mean ± SE. 
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RESULTS 
Evaluation of EP receptors subtype expression in PSC 
There are four potential receptors that mediate PGE2 activity that are known to 
bind PGE2 with high affinity, EP1-4. For a preliminary screen of the EP receptor 
profile in PSC, a set of novel primers for EP1-4 were designed using 
Primerselect software, to amplify fragments of each EP receptor by reverse 
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transcription-PCR (RT-PCR; each according to Genbank annotations nm-
000955, nm-000956, nm-000957, and nm-000958 for EP1-4, respectively. The 
expression of EP receptors in PSC cells was determined by RT-PCR using 
specific oligonucleotide primers. Each of the four bands in Figure 3.1 
corresponds to the expected PCR product sizes. EP1, 2, 3 and 4 are clearly 
expressed in PSCs (Figure 3.1).   
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Figure 3.1. EP Receptor expression. RT-PCR showing the expression of 
EP1,2,3,4 in PSC. All four EP receptor subtypes are expressed in PSC 
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EP4 receptor is required for maintaining PSCs migration and invasion 
Having shown that all four EP receptors are expressed in PSCs, it was of interest 
to determine how silencing of each EP receptor, starting with EP2 and EP4, 
affects PSC profibrogenic phenotype. To elucidate the functional role of EP 
receptors and the mechanism behind the phenotypic changes in PSC caused by 
exogenous PGE2, I silenced each of the EP receptors EP2 and EP4. RT-PCR 
shows that cells treated with siEP2 or siEP4 respectively show a reduction in 
mRNA levels of EP2 and EP4 respectively compared to the siCONTROL (Figure 
3.2.1, Figure 3.2.2). Therefore, siRNA treatment against either EP2 or EP4 
receptor is successful in inducing silencing and that the transfection with siRNA 
significantly reduced the levels of either EP2 receptor or EP4 receptor on PSC. 
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Figure 3.2 EP silencing by siRNA: PSC were transiently transfected with 
human siControl and siEP2 (1) or siEP4 (2) using Hiperfect reagent and after 72 
hours cells were harvested and RNA was extracted. RT-PCR shows the effects 
of silencing EP2 and EP4 receptors in PSC. B-actin served as a control for RT-
PCR.  
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To identify the role of EP receptor signaling in mediating PGE2 actions in 
PSC, I investigated the effects of silencing of EP2 and EP4 receptor on PGE2 
mediated functions. To examine the effects of independently silencing EP2 and 
EP4 receptor, I looked at the migration of PSC. PSC were plated in serum 
containing media, one day later, the siRNA complexes specific for EP2, EP4 and 
siCONTROL were added to the cells. After a total of 48 hours after silencing, 
PSC were trypsinized and counted. 20 000 cells were plated in the top chamber 
of the Boyden Chamber migration apparatus in serum free media. Either PGE2 
or the vehicle, DMSO were added to the bottom chambers to assay the migratory 
potencial of PSC in response to PGE2 after silencing EP2 or EP4. After 22hrs, 
cells migrated to the bottom side of the chamber were fixed with methanol and 
stained with hematoxylin and number of cells migrated or invaded was counted 
on atleast 10 fields looking under the microscope. PSC treated with siRNA 
against EP2 receptor did not show significant reduction in the rate of migration 
(Figure 3.3.1). The migrated cell number was not significantly different from the 
control.  However, PSC treated with siRNA against EP4 receptor showed a 
dramatic reduction in PSC migration (82 ± 2.906 N=3 migrated cells per area) 
compared to the siCONTROL (166.0 ± 4.359 N=3 migrated cells per field) 
(P<0.05) (Figure 3.3.1).  Therefore, EP4 silencing completely blocked the  
migratory effects of exogenous PGE2 treatment. Thus, migration of human 
pancreatic stellate cells induced by the addition of PGE2 is predominantly 
mediated through EP4.  
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In order to determine the functional role of EP2 and EP4 receptors on 
PSC invasion, a Boyden Chamber apparatus that uses Matrigel as the matrix 
was used. PSC were transfected with a scramble siRNA (siCONTROL), siRNA 
against EP2 or EP4 receptors as described in the methods section. After a total 
of 48 hours, PSC were trypsinized, counted and plated at a rate of 20 000 
cells/well in the upper chamber of the modified boyden chamber apparatus. The 
bottom wells contained 100nM of PGE2 or DMSO as a control. After 22hrs, the 
cells invaded to the bottom side of the chamber were fixed with methanol and 
stained with hematoxylin and number of cells migrated or invaded was counted 
on at least 10 fields looking under the microscope. Transfection of PSC with 
siRNA against EP2 receptor or siCONTROL did not affect PSC invasion (Figure 
3.3.2).  However, silencing of EP4 receptor greatly reduced PSC cell invasion 
through matrigel (41.33 ± 10.41 N=3 invaded cells per field) compared to the 
control (118.3 ± 13.02 N=3 invaded cells per field) (P<0.05) (Figure 3.3.2). 
Silencing of EP4 receptor but not EP2 receptor reduced both PSC migration and 
invasion 
These data collectively suggest that the effects of PGE2 on PSC migration and 
invasion are mediated by the EP4 receptor and not by EP2 receptors. Silencing 
of EP4 receptor reduced both migration and invasion of PSC to a near basal 
level. 
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Figure 3.3  Effects of EP2 and EP4 silencing on PSC  PSC were transfected 
with siCONTROL, siEP2 or siEP4 serum starved and plated in the top chamber 
of (1) a migration boyden apparatus, (2) invasion apparatus (30 x 103 cells/well). 
100nM PGE2 or the control were added to the bottom chambers. Cells were 
counted and cell migration (1) and invasion (2) were assessed. *, P<0.05   
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Enhanced expression of MMP-2 and MMP-9 is mediated by EP4 receptor 
  To further examine the functional role of EP2 and EP4 receptors in PSC, 
changes in the expression of stromal genes, identified by our microarray data as 
genes highly expressed in the stroma of PDAC, were studied. PSC were treated 
with siCONTROL, siEP2 and siEP4 separatly, for 48 hours. After a total of 48 
hours of siRNA treatment, 100nM PGE2 or DMSO (control) was added to the 
cells. PSC were incubated for an additional 24 hours with PGE2 and RNA was 
harvested. I compared cDNA from PSC treated with siCONTROL, siEP2 and 
siEP4 both treated with PGE2. Results show that PSC treated with siCONTROL 
or siEP2 showed no change in gene expression of MMP2 or MMP9. However, 
PSC treated with siEP4 had a strong reduction in the mRNA levels of  MMP2 and 
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MMP9 (Figure 3.4).   Silencing of EP2 did not have a measurable effect on 
expression of these genes in the presence or absence of PGE2.  These data 
generated using siRNA silencing of EP2 and EP4 receptor identify EP4 receptor 
as the sole mediator of PGE2 activity in PSC. Furthermore, it presents EP4 
receptor as “ the” receptor required by PSC to maintain the PGE2 dependent 
profibrogenic phenotype which included increased migration, invasion and gene 
expression. 
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Figure 3.4 RT-PCR showing the silencing effects of siEP2 and siEP4 on 
PSC gene expression. PSC transfected with siRNAs (5nM) showed a significant 
reduction in the expression of COL1a1, MMP2 and MMP-9 genes as shown by 
RT-PCR using specific oligonucleotide for MMP-2 and MMP-9 respectively. B-
actin was used as a loading control 
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Treatment of PSC with EP4 antagonist reduces the hyper activation of PSC 
To evaluate the role of EP1, EP2 as well as provide further confirmation 
for the role of EP4 receptor, specific antagonists for EP1, EP2 and EP4 receptors 
were used. PSC were plated in the migration chamber of the Boyden Apparatus 
then 10uM  of each antagonist was added to the lower chambers 1 hour prior to 
PGE2 treatment in serum free media. Treatment of PSC with antagonists for 
either EP1 or EP2 receptor did not modify cell migration as seen quantitatively 
and qualitatively by DAPI staining (Figure 3.5.1). Treatment of PSC with a 
specific antagonist against EP4 receptor show a significant reduction in cell 
migration from 239.3 ± 30.99 N=3 cells per field to 12.00 ± 5.292 N=3 cells per 
field (P<0.05) . To examine whether EP1 and EP2 receptors affect PSC invasion, 
PSC were treated independently with specific antagonists against either EP1, 
EP2 receptors. Cell invasion was measured and addition of either antagonist for 
EP1 or EP2 did not modify cell invasion, Addition of EP4 antagonist strongly 
reduced PSC invasion from 188.0 ± 16.17 N=3 cells per field to a near basal 
level with only 20.67 ± 2.333 N=3 cells per field (P<0.05)   (Figure 3.5.2). These 
results clearly demonstrate by two independent methods that EP4 receptor is 
required for PGE2-dependent PSC stimulation. Therefore, blocking stromal EP4 
receptor could be of therapeutic value for both chronic pancreatitis and the 
desmoplasia associated with PDAC. 
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Figure 3.5 Effects of specific antagonists for EP1, EP2 and EP4 on PSC  
PSC plated at 70% confluency and allowed to settle overnight. Serum containing 
media was replated with serum free media for 24 hours before addition of EP1, 
EP2 or EP4 antagonists at a dose of 10uM. 1 hour after the antagonist addition 
PGE2 was added to the cells for 24 hours. Cell migration and invasion were 
assessed by counting the number of cells that penetrated the migration 
membrane (1) or matrigel (2). *, P<0.05  
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DISCUSSION 
 
COX-2 over expression in pancreatic tumors is both biologically and 
clinically important (42, 46, 53) and the use of selective COX-2 inhibitors have 
shown great promises (168, 169). However, because of the long term side 
effects associated with COX-2 inhibitors, there is now an urgent need to identify 
targets downstream of COX-2 that mediate COX-2 activity in the hopes of 
identifying safer and more effective strategies to improve the overall prognosis of 
pancreatic cancer patients. Studies have attributed the majority of COX-2 activity 
and biological functions to PGE2 (170). Four subtypes of membrane PGE2 
receptor have been identified. They are called prostanoid receptors EP1,2,3 and 
4. The relative contribution of each of these receptors to key signaling events has 
not been fully elucidated. The role of the COX-2/PGE2 pathway in the regulation 
of the stroma of PDAC has not been studied. This study provides evidence for 
the first time that PGE2 EP receptors play a major role mediating pancreatic 
stromal hyperactivation and aims at targeting downstream effectors of COX-2 as 
an alternative way to reducing stromal hyperactivation associated with CP and 
PDAC while avoiding the unwanted effects of COX-2 inhibitors. 
 
Since there are currently no studies that investigate the role of EP 
receptors in the stroma of pancreatic cancer, the first part of this study was to 
determine the expression of EP receptors in PSC. I found that all of the EP 
receptor subtypes are expressed in PSC. 
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The four EP receptors that mediate PGE2 functions have been shown to 
control many aspects of cancer such as invasion, migration, and growth (163). 
Numerous reports have shown that blocking EP receptors as an alternative way 
to blocking COX-2 could prove to be beneficial in the clinic (163). There are no 
studies on the role of EP receptors in pancreatic desmoplasia or in PSCs. The 
proneoplastic roles of EP2 and EP4 receptors have been reported in several 
cancers (103, 110, 112, 117, 130, 134). Therefore, to evaluate the role of each 
EP receptor subtype in PSCs, I looked at EP2 and EP4 receptors first. 
Using siRNA mediated gene silencing I determined the receptor that 
mediates the profibrogenic functions of PSC. The data from this study shows that 
transfection of PSC with siEP2 did not show a significant reduction in PSC 
migration. On the other hand, silencing of EP4 receptor causes a dramatic drop 
in the migratory rate of PSC. Next, I assessed the role of EP2 and EP4 in PSC 
invasion. Similarly, silencing of EP2 receptor did not reduce PSC invasion 
through matrigel. However, when EP4 was silenced, PSC invasion was reduced 
to a near basal level even in the presence of PGE2. I also looked at the 
expression of MMP-2 and MMP-9. Silencing of EP4 only and not EP2 receptor 
reduced the mRNA gene expression of MMP-2 and MMP-9. Therefore, PGE2 
mediated MMP-2 and MMP-9 over expression is EP4 dependent. These results 
clearly identify EP4 receptor as required for PSC to be able to migrate, invade 
and alter the matrix composition. To examine the role of EP1, EP3 and further 
confirm these finding, I treated PSC with specific antagonists against EP1, EP2 
and EP4 receptors and found that inhibiting EP4 receptor only diminished PGE2 
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stimulation of PSC. EP1 or EP2 antagonists were added to PSC prior to PGE2 
treatment, and no changes in PSC migration, invasion or MMP-2/MMP-9 
expression was detected. However, treatment of PSC with the EP4 antagonist 
greatly reduced migration, invasion and gene expression of PSC. These data 
provide for the first time EP4 receptor as a potential target for the regulation of 
pancreatic stroma formation that may be useful in treatments of pancreatic 
diseases including CP and PDAC. 
A study done in lung cancer has reported that PGE2 through EP3 and 
EP4 receptor regulate the stromal formation and angiogenesis (171), and that 
inhibition of COX-2 and EP3/EP4 receptors results in reduction of the stroma and 
of CXCL12/CXCR4 axis important in mediating lung cancer metastasis. In 
pancreatic cancer, it has been shown that it is the EP2 receptor that regulates 
pancreatic cancer cells (172). PGE2 actions are mediating by its receptors EP1-
4. EP receptors are G-protein coupled receptors that mediate a variety of 
biological functions. Four EP receptor subtypes have been identified and are 
designated EP1, EP2, EP3, and EP4. EP1 signals via increased Ca2+, which leads 
to vasoconstriction. EP3 can also serve to stimulate vasoconstriction and inhibits 
the generation of cAMP, whereas EP2 and EP4 are known to mediate 
vasorelaxation by stimulating an increase in cAMP levels. A recent interest in 
studying the role of EP4 receptor in colon cancer has emerged. EP4 receptor 
targeting (117) was found to decrease foci formation, metastasis and tumor 
incidence. The role of EP receptors in the regulation of the stroma of PDAC has 
not yet been shown. Therefore, this study attempted to determine the role of EP 
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receptors in the regulation of PSC. I looked at EP2 and EP4 receptors and 
silenced by siRNA each receptor. These results show a strong inhibition of 
migration, invasion, MMP-2 and MMP-9 expression when EP4 and not EP2 
receptor is silenced. These findings suggest that EP4 receptor pathway tightly 
regulates pancreatic stellate cell activity.  
Although the role of importance of the stroma in PDAC is well known, the 
molecular mechanisms that regulate stromal activity and the downstream 
signaling involved are poorly understood. This study provides evidence for the 
first time that EP4 receptor can control major changes in the fibrogenic response 
associated with PDAC and CP. These changes include contribution to the 
formation of the fibrillar matrix, migration, invasion as well as changes in gene 
expression. I found that prostaglandin E2 EP4 receptor is responsible for the 
PGE2 induced changes in pancreatic stellate cells.  Pancreatic fibrosis 
associated with either PDAC or CP is untreatable. Evidence showing that fibrosis 
of the pancreas is tightly regulated by EP4 receptor presents it as a potential 
target for the prevention of pancreatic fibrosis or as adjuvant treatment 
administered along with treatments for PDAC.  
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CHAPTER FOUR: PGE2 ACTIVATES MULTIPLE SIGNALING PATHWAYS 
AND REGULATES COL1A1 EXPRESSION AND TRANSCRIPTIONAL 
ACTIVITY IN  PSC 
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INTRODUCTION 
  
 Pancreatic fibrosis is a characteristic of both chronic pancreatitis and the 
dense desmoplastic reaction associated with pancreatic cancer. The cellular and 
molecular mechanisms that control pancreatic fibrosis are not fully understood, 
mostly because of the lack of in vitro models. In 1998, pancreatic stellate cells 
(PSC) were discovered. They are now known to be the cells that produce the 
majority of the fibrotic reaction in the pancreas (65).    In normal physiological 
conditions, PSC are quiescent and are identified by Vitamin A fat droplets and 
positive staining for desmin and GFAP. Upon activation, PSC lose their Vitamin A 
droplets and increase their expression of alpha smooth muscle actin (a-SMA). 
Activated stellate cells express cytokines, chemokines and cell adhesion 
molecules. They also produce large amount of extra cellular matrix (ECM) 
components, mostly collagen I (65). Collagen I is the most abundant protein in 
the ECM and hyper accumulation is a characteristic of pancreatic fibrosis. 
Collagen I is formed by the polymerization of pro-α1(I) chain and pro-α2(I) which 
are generated by COL1A1 and COL1A2 genes respectively (173). COL1A1 and 
COL2A1 exist in a 2:1 ration. Pro collagen molecules have a distinct triple 
stranded rope like structure. Once they are processed outside the cell, Collagen I 
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fibrils rearrange into long fibrils that cross link to each other in the ECM, which 
gives the tensile strength and hardness to the fibrotic tissue (174). In cancers, 
study show that both the cells of the microenvironment and the collagen I matrix 
are needed for the tumor to progress. An earlier study done by Ronnov Jessen in 
1995 supports the role of collagen in tumor progression and demonstrates the 
need for both the stromal cells and the collagen I matrix for a primary breast 
cancer cell to progress to a more advanced malignant phenotype (175). Primary 
breast cancer cells were plated on a plastic petri dish and compared to the same 
primary breast cancer cells that were plated on a collagen matrix with 
myofibroblasts. Over a period of two weeks, the primary breast cancers cells that 
were plated on a collagen matrix in the presence of stromal cells progressed into 
an advanced stage whereas the primary cells plated on a Petri dish retained their 
primary structure therefore indicating that in order for a tumor to progress, a 
collagen rich matrix is required in addition to the myofibroblasts. 
  
 In pancreatic cancer, the content of collagen I is three times higher compared 
to the normal pancreas (176, 177). Many studies have tried to understand the 
role of collagen I in pancreatic cancer. In this study, they assessed the behavior 
of BXPC3 plated on different ECM molecules coated dishes. They found that 
BXPC3 plated on laminin or fibronectin coated plates no change in morphology 
was noted. However, when BXPC3 cells were placed on a collagen I coated 
plate, they became more spread out and aggressive (178). Also, pancreatic 
cancer cells plated on a collagen I matrix presented a reduction in E-cadherin, 
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enhanced proliferation and migration compared to the cells plated on matrigel. 
These results show that collagen I triggers the EMT of pancreatic cancer cells 
(179). In the same study, collagen I was also shown to increase the invasion and 
metastasis of pancreatic cancer. In vivo and in vitro data from a recent study, 
show that collagen I up regulation of MT1-MMP contributes to gemcitabine 
resistance of pancreatic cancer (180). The clinical relevance of the collagen I 
overproduction was assessed in a study done using human PDAC samples. 
Collagen I staining of sections taken from human patients with pancreatic cancer 
demonstrates that collagen I levels in patients’ correlates with stage and 
prognosis of the disease (181). Collagen I has been well studied in pancreatic 
cancer because of the extensive desmoplasia surrounding the tumor. However, 
the majority of collagen I comes from PSCs and not the tumor. Since the 
molecular regulation of Collagen I gene in PSC is not fully understood, it is 
therefore necessary to understand the molecular mechanisms that regulate 
Collagen I in PSCs.  
  In this study, I present novel evidence for the regulation of Collagen I gene 
expression and activity by Prostaglandin E2 (PGE2). I show that PGE2 
stimulates the gene expression of COL1A1 and that this stimulation is mediated 
by EP4 receptor. I also demonstrate for the first time by doing promoter analysis 
assay that PGE2 regulates the promoter of COL1A1. Blocking EP4 receptor 
reduced the hyperstimulation of COL1A1 therefore, EP4 receptor could be a 
therapeutic target for the treatment of pancreatic fibrosis associated with chronic 
pancreatitis and pancreatic cancer. 
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          MATERIALS AND METHODS 
 
Materials 
Culture media and fetal bovine serum (FBS) were obtained from Life 
Technologies, Inc. (Rockville, MD). PGE2, was obtained from Cayman 
Chemicals. 
 
Cell Culture  
Primary human pancreatic stellate cells (PSC) were isolated using the outgrowth 
method from pancreatic adenocarcinoma samples from patients undergoing 
surgical resection and were immortalized (68)(Hwang RF, 2008). PSCs were 
maintained at 37°C in a humidified atmosphere of 5% CO2 and were grown in 
10% DMEM containing 1% antibiotic. PGE2 was purchased from Cayman 
Chemicals (Ann Arbor, MI). EP4 antagonist was obtained from ONO 
pharmaceuticals (Japan). 
 
Protein extraction and western blot 
For protein extraction, PSC in culture were washed twice with ice-cold PBS. 
Modified RIPA buffer, with addition of protease inhibitors (Sigma) and 
phosphatase inhibitors (Pierce) was used to lyse the cells. The protein lysate was 
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collected by cell scraping. Lysates were sonicated and spun down. Protein 
concentration of the supernatant was measured with Bio-Rad reagent. 30-50 µg 
of protein was loaded per well of the SDS-PAGE gel. Electrophoresis was 
performed and the proteins were transferred onto a nitrocellulose membrane and 
immunoblotted. Precision plus dual color protein standards served as a 
molecular weight marker. The following antibodies were used: phospho CREB 
ser 133 and total CREB (Upstate), phospho-AKT, total AKT (Cell Signaling), 
Actin (Abcam). Fluorescent goat anti-rabbit 800 and goat anti-mouse 680 (LiCor) 
secondary antibodies were used. The bands were visualized, using Odyssey 
scanner and quantified with the manufacturers software. 
 
Reverse transcription-PCR 
 Total RNA was isolated from PSC with and without siRNA transfection and the 
quality of RNA was tested as mentioned previously. DNAse was used to remove 
contaminating genomic DNA and RNA purification. Quality of the RNA was 
confirmed by running on a denaturing gel, and we have observed clear 28S and 
18S rRNA bands. A non reverse transcribed control was used to assure that no 
genomic DNA was amplified.  Primers were designed for human   
Collagen 1A1 (5’ TGTCCACCGAGGCTCCCAGAAC 3’) (5’ 
CCCAGGCTCCGGTGTGACTCGTG 3’) 
The amplified products were separated on 1.5% agarose gels and visualized by 
ethidium bromide. Primers designed for β-actin (Genbank BC_016045), which 
  
 
94 
was used as a loading control for the PCR reactions, were forward 5' ATG ATA 
TCG CCG CGC TCG TCG TC 3' and reverse 5' CGC TCG GCC GTG GTG GTG 
AA 3'. 
 
Promoter cloning of COL1A1 
 PCR was done to amplify the full length COL1A1 promoter region using the 
following primers forward 5’ CTG CCC ACG GCT AGC CGG CCA GCC GAC 3’ 
and reverse 5’ GCC GGA GGT CCA CAGA TCT GAA CAT GTC 3’. The PCR 
product was then cut using NheI and BglIII enzymes to get the full length 
promoter. In order to get ligate the promoter to luciferase, DNA ligase enzyme 
was used. 
 
Functional Promoter Analysis of COL1A1 
 Various lengths of DNA fragments upstream of the initiating ATG codon were 
PCR amplified and inserted into luciferase reporter vector pGL3, a promoter 
vector (Promega) to analyze the promoter of COL1a1. First, the FL COL1A1 
promoter was cut with several restriction enzymes to generate plasmids with 
different sizes. StuI was used to cut the FL1853 bp COL1A1 promoter and 
generate a 1067 bp which was cut with NheI and AvrII restriction enzymes. The 
generated fragment of 868 bp was cut with StuI and EcoRV enzymes which 
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resulted in a 564 bp fragment. Cutting the 564 bp fragment with pvuII generated 
a 376 bp fragment. 
 
Transient DNA transfection 
Transient transfection of luciferase reporter plasmids was performed using 
LipofectAMINE (Life Technologies, Inc., Gaithersburg, MD), according to the 
protocol recommended by the manufacturer. Briefly, cells were seeded at about 
70% confluency in a 24 or 6 tissue culture dish in serum containing media for 24 
hours. Then, PSCs were treated with transfection mixtures containing 400 ng and 
2ug for 24 and 6 well plates respectively, of luciferase reporter plasmids and 0.5 
mg of promoterless as a negative control vector for 7 h at 37°C. Then, 3 ml of 
growth media were added to the cells, followed by incubation for an additional 16 
h. The cells were then serum starved for 16-18 hours before PGE2 or the vehicle 
addition and harvested 72 h after the transfection. As a positive control, PSC 
were transfected with GFP-luc vector in the same experimental conditions and 
GFP expression was assessed by fluorescent microscope (Olympus). 
Luciferase Assays 
After a total of 70 hours since transfection the media was replaced with luciferin 
containing media. 15ug/ml luciferin in PBS was added to each well and luciferase 
activity was assessed by measuring the signal using IVIS machine using the 
automatic settings.  
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Statistical analysis 
All experiments were conducted in triplicates and carried out on three or more 
separate occasions. Data presented are means of the three of more independent 
experiments +/- standard error mean (SEM). Statistical analysis was done using 
Graph Pad Prism (GraphPad Software). Comparisons were made using two-
tailed Student's t test and significant difference was defined as P < 0.05. Data are 
shown as mean ± SE. 
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RESULTS 
PGE2 regulates CREB levels 
PGE2 is reported to increase cAMP levels and activate PKA/CREB signaling 
pathway. Furthermore, CREB has been shown to be involved in migration and 
metastasis. Therefore, to determine whether the CREB pathway is activated by 
PGE2 in PSC, cell lysates treated with several time points of PGE2 were 
isolated. Using a specific antibody against phosphorylated CREB (ser 133), 
western blot analysis determined that PGE2 increases the phosphorylated levels 
of CREB at 10 and 15mins (Figure 4.1). Therefore, suggesting that there might 
be EP receptor specificity for mediating PGE2 functions in PSC (162). 
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Figure 4.1 PGE2 induces cAMP response element binding protein (CREB) 
in PSC (1) Western Blot of phosphor and total CREB at 0,5,10,15,30,45,60 mins 
after stimulation with PGE2 in PSC. PGE2 induces phosphorylation of CREB at 
ser 133 residue (2) Densitometry analysis of the relative amounts of total CREB 
and p-CREB from 3 separate experiments (n=3). Values are the  mean and SEM. 
*, P<0.05   
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Regulation of AKT by PGE2 
A number of signaling pathways is reported to regulated cell motility. The 
PI3K/AKT pathway has been shown to stimulate invasion, migration, and MMP-2 
and MMP-9 expression in many cell types (182, 183). Therefore, the PI3K/AKT 
signaling pathway was evaluated following PGE2 treatment. PSC were serum 
starved and treated with 100 nMPGE2. The levels of phosphorylated (ser 473) 
AKT were determined by western blotting analysis. The levels of phosphorylated 
AKT did not change following PGE2 treatment (Figure 4.2). 
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Figure 4.2 PGE2 does not activate Akt pathway in PSC (1) Western Blot of 
phospho and total Akt at 0, 5, 10, 15,30,45,60 mins after stimulation with PGE2 
in PSC. PGE2 does not induce phosphorylation of Akt   
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PGE2 regulates COL1A1 mRNA expression and activity 
The majority of pancreatic cancers have high levels of COL1A1 mostly 
produced by PSC, which facilitates their invasion and metastatic potential. In 
addition, previous data shows that PGE2 stimulates the expression of ECM 
molecules in PSC. Therefore, to examine the role of PGE2 in the regulation of 
COL1A1 gene expression in PSC, PSC were serum starved for 24 hours before 
PGE2 addition, RNA was extracted and RT-PCR was performed on the cDNA 
obtained. The results from the RT-PCR demonstrate a strong increase in the 
mRNA levels of COL1A1 gene after 24 hours treatment with PGE2 compared to 
the negative control treated with DMSO. In the absence of PGE2, serum starved 
PSC showed little expression of COL1A1 gene. These results demonstrate that 
PGE2 increase COL1A1 gene expression in PSC (Figure 4.3.1).  
To further investigate the role of PGE2 in the regulation of COL1A1 gene, 
transient transfection of PSC with a construct prepared from the full length 
promoter of COL1A1 gene ligated to a luciferase reporter gene was performed 
(Figure 4.3.2, 4.3.3). The results of the transfection indicate that treatment with 
PGE2 for 7 hours induced a ~2.5 fold increase in transcription (Figure 4.3.2).  In 
order to evaluate the promoter activity  of COL1A1 gene further, PSC were 
transfected with the full length COL1A1 promoter for 24 hours and PGE2 was 
added to serum starved PSC for 17 hours. Treatment of PSC with PGE2 for 17 
hours showed a steady increase in the promoter activity of COL1A1 which was 
not seen in the negative control (Figure 4.3.3). Treatment with DMSO (negative 
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control) did not stimulate COL1A1 promoter activity. These results confirmed the 
data from the previous time point done at 7 hours that PGE2 treatment causes a 
strong induction of COL1A1 promoter luciferase activity. 
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* P < 0.05
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Figure 4.3. PGE2 induces the mRNA expression and transcription of 
COL1A1. (1) 0 or 100 nM PGE2 was added to PSC after overnight serum 
starving and RNA was extracted after 24 hours of treatment. As shown by RT-
PCR conducted with respective human primers, PGE2 stimulated the expression 
of COL1A1. b-actin was used as a loading control.(2),(3) PGE2 induction of the 
transcriptional activity of COL1A1. PSC were transiently transfected with pGL3-
luc-COL1A1 promoter contruct. PGE2 (0, 100nM) was added 7 hours (2) and 17 
(3) hours before measuring luciferase activity. Luciferase activity was measured 
in photons/seconds using IVIS software. *, P<0.05 
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Analysis of the COL1A1 promoter constructs demonstrates that PGE2 
regulates several areas in the COL1A1 promoter 
To identify the core promoter essential for transcriptional activation, 5’ 
truncations of the ~1.8kb full length COL1A1 promoter were prepared and 
analyzed by luciferase assay (Figure 4.4.1). Various sized constructs ligated to a 
luciferase reporter gene were transiently transfected in PSC. PGE2 was added 
for 24 hours and luciferase activity was assessed in the presence of PGE2 for 
each construct and compared to the full length COL1A1 construct. COL1A1 
promoter activity of the 1067 bp, 868 bp, 564 bp and 376 bp constructs were 
determined after PGE2 treatment and compared to the full length COL1A1 
promoter activity and the promoterless negative control. Data obtained shows 
that PGE2 stimulates all four constructs. No statistically significant difference was 
noted between the full length COL1A1 promoter and the various sized 
constructs. As shown in Figure 4.4.2, transcriptional activity in PSC was not 
significantly different between the various truncated fragments compared to the 
full length fragment. Minimal change is activity was detected; however the 868 bp 
fragment exhibited the minimal activity. Nevertheless, these activities are still 
significant because they were several folds the activity of the promoterless 
reporter plasmid (negative control). This data suggests PGE2 regulates one or 
more areas in the COL1A1 promoter. 
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Figure 4.4 Functional analyses of regulatory regions in the COL1A1 
promoter responsible for mediating PGE2 activation of transcription. (1) 
Schematic representation of the various constructs generated by restriction 
enzyme digestion and ligated to a luciferase reporter gene. (2) ) PGE2 induction 
of the transcriptional activity of COL1A1 constructs. PSC were transiently 
transfected with each of the generated pGL3-luc-COL1A1 promoter contructs 
shown in (1). PGE2 (0, 100nM) was added for 17  hours before measuring 
luciferase activity. Luciferase activity was measured in photons/seconds using 
IVIS software. *, P<0.05 
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 Inhibition of EP4 receptor reduces COL1A1 expression and activity 
 
PGE2 signaling through EP4 receptor has been associated with 
tumorigenesis and I have previously found that PGE2 mediated PSC 
hyperactivation is EP4 dependent. I have also shown that blocking EP4 receptor 
reduces the profibrogenic phenotype of PSC by decreasing migration, invasion 
and MMP-2, MMP-9 expression that accompany high levels of PGE2. Therefore 
demonstrating that blocking EP4 receptor could be used as an anti fibrogenic 
therapy to reduces PSC activity. To further examine the role of EP4 receptor in 
hyper activation of PSC, I evaluated the role of EP4 receptor in mediating PGE2 
dependent COL1A1 stimulation. First, to determine whether PGE2 increases 
COL1A1 expression via EP4 in PSC, siRNA silencing was performed. siRNA 
silencing of EP4 receptor decreased COL1A1 gene expression in PSC treated 
with PGE2 compared to the negative control (Figure 4.5.1). To complement the 
siRNA approach, a pharmacological approach was used. A selective EP4 
antagonist (ONO) was added to serum starved PSC 1 hour prior to PGE2 
treatment and total RNA was collected. Using RT-PCR, I found that treatment of 
PSC with the antagonist prior to PGE2 blocked PGE2 stimulation of COL1A1 
mRNA (Figure 4.5.2).  These results suggest that blocking EP4 receptor by either 
siRNA silencing or pharmacologically using EP4 antagonism reduces COL1A1 
expression. 
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To determine the role of EP4 in mediating the transcriptional activation  of 
COL1A1 by PGE2, PSC were transiently transfected with the full length COL1A1 
promoter construct. After 24 hours of serum starvation, PSC were treated with 
EP4 antagonist 1 hour prior to addition of PGE2 for 17 hours. Luciferase activity 
was measured after a total of 70 hours after the transfection. The increase in 
COL1A1 transcriptional activity caused by PGE2 addition was reduced to a near 
basal level when EP4 antagonist was added compared to the DMSO treated 
negative control. Therefore, EP4 antagonist nullifies the actions of PGE2 hyper 
activation of COL1A1 promoter (Figure 4.5.3).  
These results demonstrate that EP4 receptor is require for PGE2 to 
increase COL1A1 activation and that blocking EP4 receptor by both siRNA and 
EP4 antagonist reduces both the expression and the transcriptional activity of 
COL1A1 caused by high levels of PGE2. 
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Figure 4.5 Effects of blocking EP4 receptor on COL1A1 expression and 
transcription (1) PSC transfected with siRNAs (5nM) showed a significant 
reduction in the expression of COL1A1 gene as shown by RT-PCR using specific 
oligonucleotide for COL1A1. B-actin was used as a loading control. (2) PSC 
treated with 10uM of the EP4 antagonist 1 hour prior to PGE2 (100nM) addition 
showed a significant reduction in the expression of COL1a1 gene compared to 
the control as shown by RT-PCR using specific oligonucleotide for COL1A1. B-
actin was used as a loading control. (3) PGE2 induction of the transcriptional 
activity of COL1A1 was blocked by EP4 antagonism. PSC were transiently 
transfected the full length pGL3-luc-COL1A1 promoter contruct. PGE2 (0, 
100nM) was added for 8 hours before measuring luciferase activity. EP4 
antagonism reduced PGE2 dependent activation of COL1A1 promoter. 
Luciferase activity was measured in photons/seconds using IVIS software. *, 
P<0.05 
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DISCUSSION 
 
 Pancreatic fibrosis is a common feature in chronic pancreatitis and 
desmoplasia associated with pancreatic cancer. Pancreatic fibrosis is associated 
with inflammation and high levels of COX-2/PGE2 (132) I have previously shown 
for the first time that PGE2 promote the fibrogenic response by increasing the 
overall activity of PSC. To further understand the molecular mechanisms of 
PGE2 mediated pancreatic fibrosis, I looked at the downstream signaling 
pathways activated in PSC by PGE2 and at the role of PGE2 in Collagen I 
hyperstimulation. Since previous data show a strong for EP4 receptor in 
mediating PGE2 hyper activation of PSC functions, I looked at CREB and AKT 
pathways known to be activated by EP4 receptor (103). I found that PGE2 does 
not activate AKT pathway in PSC. AKT is known to be involved in survival and 
evasion of apoptosis. I have previously found that PGE2 does not affect PSC 
apoptosis and survival therefore; this data further confirms that PGE2 is not 
involved in survival of PSC. I also looked at CREB and found that PGE2 induces 
the expression of phosphor CREB (ser 133) in PSC; Therefore, suggesting that 
PGE2 could activate the transcriptional potential of CREB. Collagen I is the most 
fibrous collagen and about 84% of the collagen synthesized by fibroblast (184). 
PSC produce the majority of Collagen I associated with fibrosis (63, 65). In 
pancreatic cancer, Collagen I overproduction has been correlated with increased 
tumor growth, metastasis, invasion, angiogenesis and EMT (178, 180, 181, 185, 
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186). Collagen I has also been found to correlate with poor prognosis and 
gemcitabine resistance (180, 181). Therefore, Collagen I is clearly important for 
the development and progression of pancreatic cancer. It is known that active 
PSC deposit tremendous amounts of Collagen I which serves as a matrix where 
the tumor and the stroma communicate by exchanging factors. Studies have 
shown that the normal Collagen IV rich basement membrane is slowly replaced 
by a fibrotic Collagen I matrix which triggers PSC migration and proliferation in 
order to propagate the fibrotic response. Collagen I is needed for the formation of 
the fibrotic matrix which serves as an anchorage site for cells and as storage for 
cytokines and growth factors that provide signaling clue to the stroma and cancer 
cells. However, how Collagen I gene is regulated at the molecular levels is still 
not fully understood. Collagen I is composed of two polypeptide chains proα1 and 
proα2 in the ratio of 2:1. COL1A1 and COL1A2 genes control the synthesis of the 
two chains. Several studies have shown that the over production of Collagen I 
during the fibrotic process is largely due to an increase in the transcription rate 
(187, 188). The major cytokine reported to regulate the COL1A1 gene which is 
more abundant than COL1A2 is TGF-β (189). Numerous efforts have been made 
to identify the pathways that regulate the COL1A1 transcription and earlier 
studies identified TGF-β responsive sequences in the COL1A1 promoter which 
contain binding sites for Sp1, smad and AP1 (188). PGE2 was previously shown 
to stimulate PSC activity and alter the extra cellular matrix composition by 
increasing the expression of several ECM genes like fibronectin and elastin. 
Therefore, in order to further investigate the mechanism of PGE2 mediate PSC 
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activation at the molecular levels, I hypothesized that PGE2 stimulates hyper 
activation of PSC by increasing COL1A1 expression and transcriptional 
activation. The results of this study demonstrate that PGE2 has marked effects 
on Collagen I over production, by PSC.  First, I show that PGE2 increases the 
mRNA expression of COL1A1 gene which is concurrent with the previous data 
that show that PGE2 stimulates ECM genes. In order to identify the role of PGE2 
in the transcriptional regulation of COL1A1, the full length 1.8 kb promoter was 
cloned and ligated to luciferase reporter gene then transiently transfected in 
PSC. Luciferase readings show that PGE2 treatment induces the activation of 
COL1A1 transcription at several time points. This suggests that COL1A1 
promoter might have important regulatory sequences controlled by PGE2.To 
perform a functional analysis of the upstream sequences of COL1A1, several 
chimeric constructs containing DNA fragments of various sizes were generated 
by restriction enzyme digestion. Fragments were ligated to luciferase reporter 
gene and their expression was examined after transient DNA transfection of 
PSC. Maximum transcriptional activity was noted when the full length promoter 
sequence was included. Minimal activity was detected with the transfection of the 
868 bp segment. However, the differences were not significantly different and 
PGE2 induced the activity of all the segments generated. These results indicate 
that PGE2 regulate one or more region of the COL1A1 promoter. It could also 
indicate the PGE2 regulates the 376 bp region included in all five constructs. 
CREB (cAMP-response-element-binding protein) is a transcription factor that 
binds to cAMP-responsive element (CRE) promoter sites to regulate the 
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transcription of  genes involved in a variety of physiological functions including 
cancer and inflammation(190). Previous data show that PGE2 stimulates the 
phosphorylation of CREB at ser133. The phosphorylation of CREB at this residue 
triggers the relocalization of CREB to the nucleus where it could act as a 
transcription factor or activator (190). Analysis of the COL1A1 promoter by TF 
search software showed that CREB has four binding sites. The four CREB 
binding sites are located within the 376 bp fragment generated by restriction 
enzyme digestion. Preliminary data based on siRNA studies show that silencing 
of CREB reduces the COL1A1 gene expression (data not shown) therefore, 
CREB could be mediating the PGE2 dependent transcriptional activation of 
COL1A1 by either being the transcription factor that binds to the 376 bp region or 
by being a co-activator. Nevertheless, the goal of this study is to identify the 
molecular mechanisms behind PGE2 mediates pancreatic fibrosis by looking at 
the mechanisms that govern COL1A1 hyper stimulation and identifying the 
transcription factor is beyond the scope of this study. To further investigate the 
mechanisms of COL1A1 stimulation by PGE2, I looked at EP4 receptor. Previous 
data show that EP4 mediates the majority of PGE2 dependent PSC profibrogenic 
activity. Similarly, the results of this study show that blocking EP4 receptor by 
either transfecting with siRNA against EP4 receptor or pharmacologically by 
using an EP4 antagonist, approved for the use on humans in Japan, reduces 
both the expression and the transcriptional activity of COL1A1 gene. Therefore, 
this study demonstrates for the first time a PGE2/EP4 dependent mechanism of 
COL1A1 regulation that has not been shown previously. TGF-β has been shown 
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to regulate COX-2/PGE2 and is the major regulator of COL1A1 transcription; 
therefore an argument could arise that the effects of PGE2 on COL1A1 could be 
that of TGF-β. However, TGF-β regulation of COL1A1 has been shown to be a 
SMAD dependent mechanism that is independent of PGE2. Therefore, blocking 
EP4 receptor would not reduce COL1A1 stimulation by PGE2 to a near basal 
level if TGF-β was the sole regulator of COL1A1. The reduction of COL1A1 
activation observed by blocking EP4 receptor could be potentially used as a 
therapeutic approach to reduce fibrosis.  
 In summary, the data presented in this study indicate an important role for 
PGE2 in the regulation of hyper activation of PSC seen in PDAC. As PGE2 is 
overproduced by PSC, it could represent an important step in the development of 
pancreatic fibrosis during chronic pancreatitis and pancreatic cancer. This study 
also identifies EP4 receptor as a possible target for the selective inhibition of 
PGE2 dependent COL1A1 hyper stimulation that defines hyper activation of the 
stroma. 
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CHAPTER FIVE: SUMMARY AND FUTURE DIRECTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
119
 
SUMMARY 
  
 Pancreatic cancer is one of the most lethal diseases of our times. It is the 4th 
leading cause of cancer related death in western countries including the US. Also 
called the “silent killer” because of the absence of symptoms in patients, 
pancreatic cancer is detected at a late stage when patients already develop 
metastases. In rare cases, pancreatic cancer is detected early and is resectable 
however; approximately 80% of patients still succumb to his disease and die 
within 5 years of resection because of reoccurance and metastasis. Pancreatic 
cancer is highly resistant to chemotherapy. Despite the extensive research done 
to identify novel therapies for PDAC, gemcitabine is still the first line therapy and 
the response rate is very low. Recent emphasis has been on the extensive 
desmoplastic reaction that surrounds pancreatic cancer. Pancreatic desmoplasia 
has been shown to impede proper drug delivery to the tumor and decrease 
survival in mice by acting as a barrier that shields the tumor. Tumor stroma 
interactions in pancreatic cancer are highly bidirectional. The stroma produces 
high levels of factors that aid tumor progression, such as MMP-2 which increases 
angiogenesis of the tumor, and vice versa the tumor produces cytokines and 
growth factors such as TGF-β and PDGF which activate the stroma. 
Inflammatory molecules such as COX-2/PGE2 have been reported to be high in 
both chronic pancreatitis and pancreatic cancer which share a common 
denominator; hyper activation of PSC. However, the role of COX-2/PGE2 in 
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hyper activation of the stroma is not known. The PSC has been identified as the 
major cell that produces the fibrotic reaction. Activation of PSC is followed by an 
increase in proliferation, migration, gene expression and collagen I deposition. 
Understanding how the stroma is regulated could lead to the identification of 
stroma specific targets that can reduce or block desmoplasia which can reduce 
chemoresistance, increase pancreatic cancer diagnosis, prevent metastasis, 
tumor growth and reduce the tumor burden which will increase patients’ survival. 
 Therefore, more research to increase the understanding of the pancreatic 
stellate cell (PSC) to put us one step closer to finding the cure of pancreatic 
cancer and increasing patient lives. The hypothesis of this dissertation was that 
PGE2 regulates stromal hyperactivation by amplifying PSC “profibrogenic” 
phenotype and COL1A1 activity via EP4 receptor which may be an important 
target for the treatment of this pathology. 
 To address this hypothesis, I first assessed the effects of PGE2 on PSC 
biology.  Since it is not known whether PSC produce COX-2/PGE2 the first step 
was to determine the presence of COX-2 and PGE2 in PSC. I found that COX-2 
was over expressed in pancreatic cancer and that PSC express COX-2 mRNA. I 
also used liquid chromatography tandem mass spectrometry to quantify the 
levels of PGE2 in PSC and found PSC to possess high levels of PGE2 both 
intracellular and extracellular. PGE2 levels were the highest among all 
ecosanoids profiled. Therefore, the high levels of stromal PGE2 could have an 
effect on PSCs. To address this question, I dissected the “fibrotic reaction” 
associated with pancreatic cancer based on the literature. Upon activation, PSC 
  
 
121
proliferate which causes an increase in gene expression. Once activated PSC 
migrate and penetrate through the membrane while depositing huge amounts of 
ECM mostly collagen I which forms a newly fibrotic matrix rich in collagen I.  The 
collagen I rich matrix replaces the normal basement membrane made of 
Collagen IV. Collagen IV degradation by MMPs increases. To determine the 
effects of PGE2 on PSC, changes in each step mentioned above was studied 
after PGE2 treatment. I found that stimulation of PSC by PGE2 increases all of 
the above mentioned steps of the “fibrotic reaction” including migration, invasion, 
gene expression of ECM molecules such as fibronectin, elastin, HSPG2 and 
others. A panel of MMPs was also evaluated and PGE2 was shown to increase 
the mRNA expression of MMP-2, MMP-9 and TIMP-1 specifically. The 
proliferation of PSC was stimulated by PGE2. The idea of PGE2 as a 
profibrogenic molecule in pancreatic cancer is being explored currently and has 
been presented at the recent American Pancreatic Association.  
 To explore the mechanism behind PGE2 mediated PSC stimulation, I 
evaluated the role of each EP receptor subtype in PSC hyper activity in the 
second aim of this dissertation. All four receptors were expressed in PSC. 
Several reports emphasize the role of EP2 and EP4 in tumor development and 
progression therefore, the first part aimed at silencing EP2 and EP4 in PSC and 
measuring changes in migration, invasion and looking at the mRNA expression 
of MMP-2/MMP-9. I found that silencing only EP4 receptor and not EP2 resulted 
in a near complete blocking of PGE2 dependent stimulation of migration, 
invasion and gene expression. These results suggest that EP4 is required for 
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PSC activity. To assess the role of EP1 and EP3, and to further confirm the 
results of the siRNA silencing, I used a pharmacological approach. Specific 
chemical antagonists against each EP receptor were obtained. PSC treated with 
each antagonist were subjected to migration, invasion assays as well as gene 
expression studies. The data from this study confirm that only EP4 receptor is 
required for PGE2 to stimulate PSC activity. Blocking EP4 receptor resulted in a 
reduction to a near basal level of many of PSC profibrogenic functions such as 
migration, invasion and gene expression therefore, identifying EP4 receptor as a 
potential therapeutic target for hyper activation of the pancreatic stroma. Blocking 
EP4 may reduce the desmoplastic reaction surrounding pancreatic cancer and 
help overcome the problem of impeded drug delivery to the tumor caused by 
desmoplasia in pancreatic cancer. 
 The third aim of this dissertation is to identify the molecular mechanism by 
which PGE2 regulates PSC by studying COL1A1 gene regulation. I 
demonstrated that PGE2 regulates the expression of COL1A1. I also cloned the 
COL1A1 full length promoter and ligated it to a luciferase reporter gene to 
determine the transcriptional activation of COL1A1 by PGE2. I found that PGE2 
induced the promoter activation of COL1A1 in as little as 7 hours. I also did 
functional studies to analyze the promoter of COL1A1 by generating various 
fragments of the COL1A1 promoter. Analysis of the 5’ truncations of the promoter 
revealed that the transcriptional activity of all four truncations increased with 
PGE2 treatment. These findings suggest that PGE2 may regulate elements 
present in the 376 bp region that is common to all four truncations. Bioinformatics 
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analysis of the COL1A1 promoter identified several CREB binding sites in the 
COL1A1 promoter particularly in the 376 bp region. Furthermore, PGE2 was 
found to increase the phosphorylation of CREB at ser133 which triggers its entry 
to the nucleus to act as a transcription factor. Therefore, one possibility could be 
that CREB regulates the 376 bp region of COL1A1. However, identifying the 
transcription factor that regulates COL1A1 is beyond the scope of this study. 
 Since blocking EP4 reduced the overall fibrogenic phenotype of PSC, I 
explored the role of EP4 receptor in PGE2 mediated COL1A1 activation of 
transcription and expression.  I demonstrated that EP4 receptor is required for 
PGE2 to induce COL1A1 expression and transcriptional activity by both silencing 
by siRNA EP receptor and by using a pharmacological antagonist. These results 
identify a novel mechanism by which COL1A1 is regulated. 
 In conclusion, this work demonstrates that PSC produce high levels of PGE2 
and that PGE2 regulates the profibrogenic phenotype of PSC by stimulating 
migration, invasion, ECM production and degradation. Moreover, blocking each 
EP receptor showed that only EP4 receptor is required in PGE2 mediated 
stimulation of PSC. Furthermore, this study delineates for the first time that PGE2 
regulates the expression and transcriptional activity of COL1A1 via EP4 receptor. 
Blocking EP4 receptor results in a complete reduction of PSC activation and 
COL1A1 activity therefore, this study identifies EP4 receptor as a potential 
therapeutic target for pancreatic fibrosis associated with chronic pancreatitis and 
pancreatic cancer. 
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FUTURE DIRECTIONS 
 
Will blocking EP4 receptor in PSC reduce desmoplasia and increase 
gemcitabine effectiveness in vivo? 
 
 In order to show the effect of blocking the production and function of PGE2 on 
pancreatic fibrosis by targeting EP4 receptor in vivo studies are needed. A 
mouse model of orthotopic implantation of pancreatic cancer (human) with 
associated stromal production (mouse) will be used. 
 Preliminary data from experiments on 14 pancreatic cancer cells, CAPAN- 2 
(ATCC) and primary pancreatic cancer cells freshly isolated from pancreatic 
cancer patients cultured in our laboratory (MDAPaCa-1) extensively produced 
pancreatic cancer associated fibrosis as seen by H & E staining (Figure 5.1). 
MDAPaCa-1 cells were further manipulated to express firefly luciferase to be 
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used for bioluminescence in vivo imaging. In this study, MDAPaCa-1 would be 
used orthotopically to develop pancreatic cancer and its associated fibrosis. 
Preliminary data indicate that liposomal delivery of siRNA is capable of 
sustaining silencing for 3 days (Figure 5.2). 
 In this model, the effect of blocking EP4 on PSC will be studied by treating the 
mice every 3 days with either with neutral liposome couple siRNA [A] 
siCONTROL or with [B] mouse siRNA against EP4 receptor to specifically target 
the stroma. A and B will further be divided into two groups each, treated with 
Gemcitabine or Saline solution as a negative control. The rationale behind each 
treatment will be: Since the cancer formed will be human and the stroma will be 
mouse, administering mouse siEP4 will inhibit COX-2 production in the mouse 
stroma, thus reducing PGE2 production and hence will the effects on mouse 
stromal cells. After confirming that mouse siEP4 administration reduces PSC 
activation and the stroma, treatment with gemcitabine would answer the question 
whether reduction of the stroma would increase chemosensitivity. Survival, tumor 
growth and metastasis would be assessed. 
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Figure 5.1 H& E staining of pancreatic tumor showing fibrosis. Primary 
pancreatic cancer cell line (MDAPaCa1) isolated from human pancreatic cancer 
patients was used to develop orthotopic pancreatic cancer. H & E staining 
showed extensive fibrosis formation.  
 
 
 
 
 
 
 
 
 
 Figure 5.2 Silencing luciferase in vivo by neutral liposome coupled siRNA 
against luciferase gene. Panc-1 bearing firefly luciferase was orthotopically 
injected in mice and tumor was developed. Neutral liposomes coupled against 
siRNA luciferase were injected i.p. and bioluminescence imaging showed 
significant silencing at 1-3 days. Luciferase activity was expressed as 
photons/seconds.   
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             How does CREB regulate COL1A1? 
 
 Pancreatic cancer is characterized by excessive deposition of Collagen Ia1 by 
PSC surrounding the tumor. The increase in stromal Collagen I in pancreatic 
cancer has been linked to EMT, survival, invasion and metastasis. Collagen Ia1 
deposition by stellate cells is central for the development and progression of 
cancer associated fibrosis, however the molecular mechanism leading to the up 
regulation of collagen I levels by PSC in pancreatic cancer is unknown. Previous 
data show that PGE2 stimulates the production of extra cellular matrix genes via 
EP4. Particularly, PGE2 increases the expression of Collagen 1a1. a key 
component of the fibrilar matrix formed during pancreatic cancer. Silencing of 
PGE2 EP4 receptor only greatly reduces collagen Ia1 expression. Previous 
studies also show that PGE2 stimulates the expression of phosphor CREB ser 
133. One CREB is phosphorylated at that residue, its transcriptional potential is 
activated and CREB enters the nucleus to act as a transcription factor. 
Furthermore, analysis of the region upstream of Collagen Ia1 promoter showed 
multiple binding sites for CREB (Figure 5.3). Many of the cellular effects caused 
by the activation of cAMP/PKA pathway are mediated by the phosphorylation of 
CREB on Ser 133. This study would determine the potential role of EP4 
mediated cAMP/PKA dependent transcriptional regulation of Collagen Ia1 by 
CREB. 
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 The downstream signaling effectors that mediate PGE2 EP4 receptor up 
regulation of Collagen 1 will be determined. cAMP EIA assay will be performed 
on PSC with or without PGE2 treatment and siEP4 PSC treated with PGE2. This 
assay will be used to determine whether PGE2 activation of EP4 receptor will 
result in the activation of cAMP. The agonist Forksolin will be used to determine 
whether PGE2 stimulation of Collagen Ia1 will be cAMP dependent by Luciferase 
assay on PSC pGL3-E-COL1A1-Luc.L3.6 cell line will be used as a positive 
control. To determine whether Collagen Ia1 up regulation by PGE2 is dependent 
upon the transcriptional activation of CREB, a mutation of the ser 133 site to 
alanine will be done and Collagen Ia1 promoter luciferase assay would determine 
if CREB might transcriptionally regulate Collagen Ia1. Promoter analysis using 
restriction enzyme digestion of collagen 1a1 would be used to identify potential 
binding region for CREB that are PGE2/EP4 dependent. Point mutation in the 
CREB binding region of collagen 1 promoter would identify the precise CREB 
binding site that could be activated by PGE2. EMSA and ChIP assay will 
determine the direct binding of CREB to the site that will be identified as the 
CREB binding site of the Collagen Ia1 promoter that will be caused by PGE2 
treatment and that will be EP4 dependent. 
 Mutant construct for CREB binding domains would identify a binding site for 
CREB in the promoter region of Collagen Ia1 that would be activated by PGE2 
and EP4 dependent.  
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Figure 5.3 Bioinformatics analysis of COL1A1 promoter identifies four 
putative binding sites for CREB. 
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